**Name of Journal:** *World Journal of Diabetes*

**Manuscript NO:** 69255

**Manuscript Type:** EXPERT RECOMMENDATIONS

**Expert opinion on the preoperative medical optimization of adults with diabetes undergoing metabolic surgery**

Bhattacharya S *et al.* Preoperative optimization before metabolic surgery in diabetes

Saptarshi Bhattacharya, Sanjay Kalra, Nitin Kapoor, Rajiv Singla, Deep Dutta, Sameer Aggarwal, Deepak Khandelwal, Vineet Surana, Atul Dhingra, Viny Kantroo, Sachin Chittawar, Nilakshi Deka, Vivek Bindal, Puja Dutta

**Saptarshi Bhattacharya,** Endocrinology, Max Superspeciality Hospital, New Delhi 110092, India

**Sanjay Kalra,** Endocrinology, Bharti Hospital, Karnal 132001, Haryana, India

**Nitin Kapoor,** Endocrinology, Christian Medical College, Vellore 632004, Tamil Nadu, India

**Rajiv Singla,** Endocrinology, Kalpavriksh Super Speciality Center, New Delhi 110075, India

**Deep Dutta,** Endocrinology, CEDAR Superspecialty Clinic, New Delhi 110075, India

**Sameer Aggarwal,** Endocrinology, Apex Plus Superspeciality Hospital, Rohtak 124001, Haryana, India

**Deepak Khandelwal,** Endocrinology, Maharaja Agrasen Hospital, New Delhi 110026, India

**Vineet Surana,** Endocrinology, Manipal Hospitals, New Delhi 110075, India

**Atul Dhingra,** Endocrinology, Gangaram Bansal Super Speciality Hospital, Sri Ganganagar 335001, Rajasthan, India

**Viny Kantroo,** Respiratory Medicine & Critical Care, Indraprastha Apollo Hospitals, Sarita Vihar, New Delhi 110076, India

**Sachin Chittawar,** Endocrinology, Gandhi Medical College, Bhopal 462001, Madhya Pardesh, India

**Nilakshi Deka,** Endocrinology, Apollo Hospitals, Guwahati 781005, Assam, India

**Vivek Bindal,** Minimal Access, Metabolic and Bariatric surgery, Max Superspeciality Hospital, Patparganj, New Delhi 110092, India

**Puja Dutta,** Nutrition, Max Superspeciality Hospital, Patparganj, New Delhi 110092, India

**Author contributions:** Bhattacharya S, Kalra S, and Singla R conceived the study; Kapoor N, Kandelwal D, Dutta D, and Surana V conducted the literature search; All authors attended a meeting held at the sidelines of the Annual Society for Promotion of Education in Endocrinology and Diabetes Conference in February 2020, and multiple virtual meetings were attended by the authors to reach a consensus on controversial topics; Bhattacharya S, Chittawar S, Dutta P, and Deka N prepared the initial draft of the manuscript; Aggarwal S, Dhingra A, Bindal V, and Kapoor N revised the manuscript; All authors have read and approved the final manuscript.

**Corresponding author:** **Saptarshi Bhattacharya, FACE, MD, Doctor,** Endocrinology, Max Superspeciality Hospital, Patparganj, 108A I P Extension, New Delhi 110092, India. saptarshi5@yahoo.com

**Received:** June 23, 2021

**Revised:** July 18,2021

**Accepted:** August 25, 2021

**Published online:** October 15, 2021

**Abstract**

Diabetes mellitus (DM) and obesity are interrelated in a complex manner, and their coexistence predisposes patients to a plethora of medical problems. Metabolic surgery has evolved as a promising therapeutic option for both conditions. It is recommended that patients, particularly those of Asian origin, maintain a lower body mass index threshold in the presence of uncontrolled DM. However, several comorbidities often accompany these chronic diseases and need to be addressed for successful surgical outcome. Laparoscopic Roux-en-Y gastric bypass (RYGB) and laparoscopic sleeve gastrectomy (LSG) are the most commonly used bariatric procedures worldwide. The bariatric benefits of RYGB and LSG are similar, but emerging evidence indicates that RYGB is more effective than LSG in improving glycemic control and induces higher rates of long-term DM remission. Several scoring systems have been formulated that are utilized to predict the chances of remission. A glycemic target of glycated hemoglobin < 7% is a reasonable goal before surgery. Cardiovascular, pulmonary, gastrointestinal, hepatic, renal, endocrine, nutritional, and psychological optimization of surgical candidates improves perioperative and long-term outcomes. Various guidelines for preoperative care of individuals with obesity have been formulated, but very few specifically focus on the concerns arising from the presence of concomitant DM. It is hoped that this statement will lead to the standardization of presurgical management of individuals with DM undergoing metabolic surgery.

**Key Words:** Diabetes; Obesity; Metabolic surgery; Bariatric surgery; Remission of diabetes

**©The** **Author(s) 2021.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Bhattacharya S, Kalra S, Kapoor N, Singla R, Dutta D, Aggarwal S, Khandelwal D, Surana V, Dhingra A, Kantroo V, Chittawar S, Deka N, Bindal V, Dutta P. Expert opinion on the preoperative medical optimization of adults with diabetes undergoing metabolic surgery. *World J Diabetes* 2021; 12(10): 1587-1621

**URL:** https://www.wjgnet.com/1948-9358/full/v12/i10/1587.htm

**DOI:** https://dx.doi.org/10.4239/wjd.v12.i10.1587

**Core Tip:** The ambit of metabolic surgery for diabetes has increased. Individuals with inadequate glycemic control can be considered for surgery if less severely obese, and even more so if they are of Asian origin. However, both diabetes and obesity are associated with multiple comorbidities that require optimization before surgery. There are several clinical guidelines for the preoperative management of individuals with obesity; however, specific suggestions addressing these concerns in persons with diabetes have not been recommended. It is important to achieve optimal glycemic control and diagnose and manage cardiovascular, pulmonary, gastrointestinal, and renal complications before surgery. Nutritional assessment, psychological evaluation, and ruling out specific endocrine disorders are other essential adjuncts. These guidelines will help to standardize the management of preoperative comorbidities and improve postoperative outcomes in individuals with diabetes who opt for metabolic surgery.

**INTRODUCTION**

The twin epidemics of diabetes mellitus (DM) and obesity have enormous medical as well as financial implications. Both are chronic and usually life-long conditions with very few definitive therapeutic choices that alter their natural course[1].Metabolic surgery, which was commonly designated earlier as bariatric surgery, has emerged over the last three decades as a potentially disease-modifying option for both these disorders. The terms “bariatric surgery” and “metabolic surgery” have often been used interchangeably. Most societies now endorse the term “metabolic surgery” as weight-dependent and weight-independent benefits of these procedures are gradually being recognized[2,3].

DM and uncontrolled hyperglycemia have emerged as important determinants of the need for metabolic surgery in individuals with obesity. DM is associated with multiple comorbidities that demand individualized attention around the bariatric procedure. Although there are several guidelines that address the preoperative concerns before metabolic surgery, none of them specifically focus on the issues arising in DM. This statement provides recommendations on preoperative medical management for individuals with DM who plan to undergo metabolic surgery.

**DEVELOPMENT OF GUIDELINES AND GRADING OF SCIENTIFIC EVIDENCE**

The expert panel met at the Society for Promotion of Education in Endocrinology and Diabetes Conference (SPEEDCON) 2020, the third annual conference of SPEED, held on 1-2, February 2020, at Gurugram, Haryana, India. The authors searched the medical literature in the PubMed related to bariatric or metabolic surgery for patients with obesity and DM. Search terms included “bariatric surgery” or “metabolic surgery”, and “diabetes mellitus” in combination with the terms related to the sections that were planned to be addressed in the statement. The latter search words included “indications”; “type of surgery” and all of the common types of metabolic surgery commonly performed *e.g.,* “laparoscopic Roux-en-Y gastric bypass,” “laparoscopic sleeve gastrectomy,” *etc.*; “remission” and “predictors of remission,” “glycemic status,” “glycemic control,” “glycemic management” with and without the term “perioperative”; “cardiovascular disease”; “hypertension,” “blood pressure,” “dyslipidemia” and “lipid profile”; “pulmonary,” “respiratory,” “tobacco,” “smoking,” “pulmonary function test,” “obstructive sleep apnea,” “obesity hypoventilation syndrome” and “venous thromboembolism”; “gastrointestinal,” “upper gastrointestinal endoscopy,” “gastroesophageal reflux disease,” and “*Helicobacter pylori*”; “hepatic,” “liver,” “non-alcoholic fatty liver disease,” and “nonalcoholic steatohepatitis”; “renal,” “kidney,” “creatinine,” “albumin-creatinine ratio,” “electrolytes,” “sodium,” “potassium,” and “uric acid”; “nutrition,” “iron,” “vitamin B12,” “folic acid,” “anemia,” “vitamin D,” “vitamin A,” “vitamin K,” “vitamin E,” “copper,” “zinc,” and “selenium”; “hypothyroidism,” “thyroid function test,” “Cushing’s syndrome,” “polycystic ovary syndrome,” “pregnancy,” “hypogonadism,” “monogenic obesity” and “syndromic obesity”; “psychological” and “behavioral”; and “preoperative weight loss,” “low calorie diet” and “very low calorie diet.”

The authors followed the system developed by the American Diabetes Association (ADA) to grade the quality of scientific evidence supporting the recommendations (Table 1)[4]. The recommendations were allotted grades of A, B, or C based on the nature of the available evidence. Expert opinion E was ascribed to recommendations that lack evidence from clinical trials, where clinical trials may not be feasible, or the available literature is inconclusive. However, it is imperative to understand that although scientific evidence and recommendations can be crucial guiding principles, the management of every patient should ultimately be individualized for each particular case[5,6].

**PROBLEM STATEMENT: PREVALENCE OF OBESITY AND DIABETES**

Obesity is a common problem that has grown into a global health and economic crisis. The World Health Organization (WHO) defines overweight and obesity as 'abnormal or excessive fat accumulation that presents a health risk’[7].According to the WHO 2016 global estimates, 39% of adults were overweight, and 13% were obese[8]. The Center for Disease Control and Prevention 2017 data suggested that 42.4% of adults in the United States of America were obese, while 9.2% were severely obese[9].

The increase in the prevalence of obesity has been accompanied by a parallel upsurge in cases of DM[10]. The International Diabetes Federation declared the current global prevalence rate of DM to be 9.3% (463 million), and predicts that it will go up to 10.2% (578 million) by 2030[11]. Both DM and obesity share a common pathogenesis, and the term "diabesity" has often been used when the two conditions coexist[12]. Obesity is recognized as a risk factor for the development of type 2 DM (T2DM)[13,14]. The coexistence of DM and obesity adversely affects the outcome of each condition and exerts an unfavorable cardiovascular impact[15].

**CLASSIFICATION OF OBESITY AND DIABETES**

The WHO has classified obesity based on body mass index (BMI). Obesity is conventionally defined as BMI ≥ 30 kg/m2, while BMI between 25.0 and 29.9 kg/m2 is defined as overweight[7]. Asians have higher body fat percentage at lower values of BMI[16,17]; thus, more stringent criteria have been used to define obesity in the Asian population[18,19]. Table 2 depicts the classification system used to define obesity internationally and for Asia.

The ADA and WHO criteria are the established methods for diagnosing DM[20,21]. The WHO does not support the use of glycated hemoglobin (HbA1c) for diagnosing DM[21]. The ADA classifies DM into four categories: Type 1 DM (T1DM), T2DM, gestational DM, and other specific types of DM[20]. T2DM is closely inter-related to obesity and comprises the predominant subtype of DM encountered in patients undergoing metabolic surgery.

**INDICATIONS FOR METABOLIC SURGERY IN DIABETES**

***Recommendation 1***

Metabolic surgery is recommendedas a therapeutic option in T2DM if the BMI is ≥ 40 kg/m2 (≥ 37.5 kg/m2 for Asians) irrespective of glycemic status (A). Surgery is also recommended as a treatment modality in T2DM with BMI between 35 to 39.9 kg/m2 (32.5 to 37.4 kg/m2 for Asians) if adequate glycemic control cannot be achieved despite standard management (B).

***Recommendation 2***

Metabolic surgery should be considered as a therapeutic option in T2DM with BMI between 30 to 34.9 kg/m2 (27.5 to 32.4 kg/m2 for Asians) if glycemic control is suboptimal despite standard management (B). However, the committee recognizes that there is limited evidence to support the long-term efficacy of metabolic surgery in Asians with T2DM and BMI < 30 kg/m2, and scrutiny of risk *vs* benefit should be undertaken before performing the procedure in patients with lower BMI (E).

***Recommendation 3***

The associated conditions that might favor a surgical approach in T2DM with obesity are poorly controlled hypertension, non-alcoholic fatty liver disease (NAFLD), obstructive sleep apnea (OSA), obesity hypoventilation syndrome (OHS), osteoarthritis of the knee or hip, urinary stress incontinence, polycystic ovary syndrome (PCOS), gastro-esophageal reflux disease (GERD), idiopathic intracranial hypertension, severe venous stasis disease, obesity-related limited mobility and poor quality of life (E).

***Discussion***

The 2nd Diabetes Surgery Summit (DSS-II) defined the eligibility for metabolic surgery in T2DM with obesity, depending on the adequacy of glycemic control in conjunction with BMI[22]. Our committee broadly endorses the criteria for metabolic surgery as specified in the DSS-II recommendations. The indication for metabolic surgery along with level of existing evidence is summarized in Table 3.

***BMI (≥ 35 kg/m2)***

Long-term efficacy of metabolic surgery in improving the outcome of T2DM with BMI ≥ 35 kg/m2 has been clearly demonstrated. Meta-analyses has shown that macrovascular and microvascular outcomes, and mortality are significantly better after metabolic surgery than medical therapy[23,24]. The meta-analysis by Yan *et al*[25] specifically looked into outcomes of studies with more than 5 years of follow-up. Surgery resulted in a lower incidence of macrovascular complications (relative risk [RR] = 0.43), all-cause mortality (hazard ratio [HR] = 0.65), lower weight, and better glycemic control compared to medical management. Long-term observational data from Swedish Obese Subjects registry also demonstrate the benefit of surgery in terms of DM remission (median follow-up 10 years) as well as macrovascular and microvascular complications (median follow-up 17.6 years for surgery and 18.1 years for controls) over medical therapy[26].

***BMI (30-34.9 kg/m2)***

Evidence also support the beneficial role of metabolic surgery in individuals with DM and BMI < 35 kg/m2[27,28]. In the meta-analysis by Müller-Stich *et al*[29] surgery resulted in a higher T2DM remission rate (odds ratio [OR] = 14.1), better rates of glycemic control (OR = 8.0) and lower HbA1c in individuals with DM and BMI < 35 kg/m2 compared to standard medical management. Long-duration randomized controlled trials (RCTs) can help further substantiate this recommendation.

***BMI (< 30 kg/m2****)*

In a meta-analysis of 12 studies done by Ji *et al*[30], 697 Asian subjects with DM and BMI < 30 kg/m2 were analyzed at 6, 12, and 24 mo after metabolic surgery. After 1 year of surgery, BMI and waist circumference decreased by 2.88 kg/m2 and 12.92 cm, respectively. Improvement in glycemic and lipid parameters was also observed at all three timepoints.Another meta-analysis of 26 studies assessed the remission of DM in subjects with a BMI < 30 kg/m2. The follow-up duration ranged from 6 to 42.1 mo, with half of the studies having data for 12 mo only. The mixed-effect meta-analysis model estimated an overall DM remission of 43% along with an HbA1c reduction of 2.08%[31]. However, long-term outcome data to support the application of metabolic surgery in Asians with DM and BMI < 30 kg/m2 is necessary before its routine clinical application.

***Comorbidities***

Metabolic surgery in subjects with obesity and DM demonstrated a favorable effect on hypertension[29,32]. The recent meta-analysis by Yan *et al*[25] however failed to show benefit in blood pressure after a minimum follow-up of 5 years. Various other obesity-related comorbidities improved after bariatric procedures, but specific evidence in subgroups with DM is lacking. The clinical practice guidelines by the American Association of Clinical Endocrinologists (AACE)/American College of Endocrinology, The Obesity Society (TOS), the American Society for Metabolic & Bariatric Surgery (ASMBS), the Obesity Medicine Association (OMA), and the American Society of Anesthesiologists (ASA) in 2019 suggested that bariatric procedures can be considered in obese subjects with BMI > 35 kg/m2 in the presence of comorbidities such as NAFLD, OSA, osteoarthritis of the knee or hip, and urinary stress incontinence. The guideline also recognized beneficial but weak evidence supporting the role of surgery for the amelioration of OHS, idiopathic intracranial hypertension, GERD, severe venous stasis disease, obesity-related limited mobility, and impaired quality of life[33]. Weak evidence also exists regarding improvement in fertility, menstrual irregularity, and hirsutism in women with PCOS after bariatric procedures[34]. Our expert committee advocates that metabolic surgery should be considered as a therapeutic option in obesity and DM, especially if associated with comorbidities that improve after bariatric procedures. However, the committee acknowledges that evidence in favor of such a recommendation is very weak and should be substantiated by further research.

**CHOICE OF THE TYPE OF METABOLIC SURGERY IN DIABETES**

***Recommendation 4***

Laparoscopic Roux-en-Y gastric bypass (RYGB) and laparoscopic sleeve gastrectomy (LSG) are the two most preferred bariatric procedures worldwide. RYGB and LSG result in equivalent long-term weight loss, with RYGB producing better glycemic control than LSG on prolonged follow-up and can be the preferred bariatric procedure in presence of DM (B). Other factors that might guide the choice of type of surgery are the risk of nutritional deficiencies resulting from malabsorption after RYGB and the possibility of GERD development after LSG. Institutional expertise can also guide the decision regarding the choice of the type of surgery (E).

***Recommendation 5***

Laparoscopic adjustable gastric banding (LAGB) is an effective procedure in inducing weight loss. The risk of complications related to the gastric band and possible need for revision surgery in the future should be taken into consideration before undertaking LAGB (B).

***Recommendation 6***

Biliopancreatic diversion (BPD) or BPD with duodenal switch (BPD-DS) is the most effective procedure in causing weight loss and remission of DM but has the maximum risk of immediate postoperative and long-term complications and should only be reserved for those having extremely high BMI (> 60 kg/m2) (B).

***Discussion***

The four standard bariatric procedures include RYGB, LSG, LAGB, BPD, or BPD-DS. There are many other variations of these procedures. Several endoscopic techniques have also emerged as means to induce weight loss in recent years. A systemic review reported the weighted means of the percentage of excess weight loss (%EWL) at 10 years or more after BPD ± DS, RYGB, LSG, and LAGB to be 74.1%, 55.4%, 57%, and 45.9%, respectively[35].

***Long-term outcome in obesity studies***

A recently published meta-analysis of 18 studies (9 RCTs and 9 non-randomized interventions) comprising 2917 participants demonstrated that both RYGB and LSG had similar efficacy in causing weight reduction and remission of DM. The postoperative complication and reoperation rates were less with LSG than RYGB. However, improvement in dyslipidemia, hypertension, and GERD was better with RYGB compared to LSG[36].Another meta-analysis of 28 studies (7 RCTs, 6 prospective observational studies, and 15 retrospective observational studies) including 9038 subjects with obesity, revealed higher remission rates of T2DM with RYGB after 3 years in comparison to the LSG group. Five-year follow-up data showed that RYGB was superior to LSG in terms of weight loss, T2DM remission, and improvement in hypertension and dyslipidemia (low-density lipoprotein [LDL])[37].

***Long-term outcome in subjects with diabetes***

In the meta-analysis by Madadi *et al*[38], T2DM remission rates in the LSG group were significantly (OR = 0.71, *P* = 0.003) less than that of the RYGB group, though the difference lost significance after 1 year. However, more DM remission was achieved with LSG compared to LAGB (OR = 2.17, *P* = 0.001) after 1 year[38]. Other meta-analyses have also demonstrated the superiority of RYGB over LSG in improving weight loss, and short and mid-term glycemic and lipid parameters in patients with and without T2DM[39,40]. Another meta-analysis revealed that DM resolution was highest after BPD (89%), followed by RYGB (77%), LAGB (62%), and LSG (60%)[41]. In STAMPEDE, one of the landmark trial in metabolic surgery, RYGB fared better than LSG at 5 years in achieving better glycemic control. Besides, the RYGB group required less medicine for glycemic control as compared to the LSG group[42]. Meta-analyses also revealed that immediate complication rates were higher after RYGB, and the risk of repeat surgery was higher after LAGB[35,43]. The postoperative and long-term complications were highest after BPD/BPD-DS, and the DSS-II statement suggested that these procedures should be reserved for extreme cases of obesity (BMI > 60 kg/m2)[22,44]. A comparison of the outcomes of RYGB and LSG in patients with DM and obesity is summarized in Table 4.

**PREDICTORS FOR REMISSION OF DIABETES**

***Recommendation 7***

Remission of DM can be defined as HbA1c < 6.5% and fasting plasma glucose (FPG) < 126 mg/dL (7 mmol/L) along with complete discontinuation of glucose-lowering therapy that persists for at least 6 mo (E).

***Recommendation 8***

We suggest that partial remission of DM can be defined as HbA1c < 5.7% and FPG < 100 mg/dL (5.6 mmol/L) persisting for at least 6 mo, when metformin is continued (E).

***Recommendation 9***

Preoperative fasting C-peptide level, younger age, shorter duration of DM, preoperative glycemic status, and pre-surgery requirement for insulin act as indices of pancreatic beta-cell reserve, and correlate with the chance of remission. BMI, visceral fat area (VFA), and waist circumference act as indicators of potential for reducing insulin resistance, and can also predict remission (A). Prediction models like DiaRem score, ABCD, and Individualized Metabolic Surgery (IMS) scores are validated methods to assess remission probability (B).

***Discussion***

**Definition of remission:** The most commonly applied criteria for defining DM remission was proposed by Buse *et al*[45]. Partial remission was defined as, HbA1c < 6.5%, and FPG between 100–125 mg/dL (5.6–6.9 mmol/L) lasting for 1 year or more after the procedure, in the absence of pharmacologic therapy. Complete remission was defined as HbA1c in normoglycemic range (< 5.7%) and FPG < 100 mg/dL (5.6 mmol/L) for at least 1 year. Prolonged remission or "cure" was considered as a complete remission lasting for 5 years or more. The stringent criteria proposed in the statement have the drawback of using different thresholds for diagnosis of DM and complete remission. Besides, many individuals who receive metformin for prophylactic purpose will not satisfy this criterion despite having HbA1c in the normoglycemic range. A definition of DM remission has also been proposed by the Association of British Clinical Diabetologists (ABCD) and the Primary Care Diabetes Society[46]. DM remission has also been defined by Kalra *et al*[47] and our panel approves the definition suggested by them. Our committee also proposes that partial remission can be defined as patients receiving metformin, and having HbA1c < 5.7% and FPG < 100 mg/dL (5.6 mmol/L) for a minimum duration of 6 mo. The HbA1c lowering effect of metformin varies between 1.12 to 0.6%. We consider that a cut-off HbA1c < 5.7% along with metformin is a reasonable approximation to the Hba1c value of 6.5% without the drug[48]. Though there is absence of outcome data in candidates receiving prophylactic metformin post-surgery, defining such a group will enable researchers to assess the usefulness of the strategy.

***Predictors for remission***

The rates of DM resolution after different types of metabolic surgery have already been discussed in the preceding section. DM remission results from the interplay of pancreatic beta-cell reserve and the potential for the decrement in insulin resistance[49].The indicators of beta-cell reserve that correlate with remission include short DM duration, absence of insulin use, better glycemic control, higher serum C-peptide levels, lower age and lesser number of DM medicines[50-55]. The surrogate indices of insulin resistance with predictive value are high baseline BMI, wider waist circumference, hepatic steatosis, VFA, and inflammatory markers such as high serum C-reactive protein (CRP) and osteopontin[50,52,53,56-60].

In the meta-analysis by Wang *et al*[61], younger age, short DM duration, better glycemic control (lower HbA1c level), and absence of insulin use, correlated with remission. Asian patients were more likely to undergo remission in the presence of high baseline BMI and elevated C-peptide levels. A nationwide register-based cohort study from Sweden revealed that the chance of achieving complete remission correlated negatively with the duration of DM, insulin treatment, age, and HbA1c at baseline. Remission rates were higher among males and those having higher BMI at baseline[54]. Other reported predictors of remission in different studies are higher liver enzymes, higher white blood cell count, serum creatinine, serum LDL cholesterol and absence of long acting insulin[59,62-64].

Visceral adipose tissue is closely linked to insulin resistance and has been explored as a marker of remission[65-67]. BMI and waist circumference however might underestimate the amount of visceral adiposity in Asian population[68,69]. VFA as assessed by magnetic resonance imaging was associated with a higher chance of remission in candidates with BMI < 35 kg/m2[57]. Visceral adiposity index (VAI) calculated from waist circumference, BMI, serum triglycerides and high-density lipoprotein is a validated marker of visceral fat content[70]. In a study from China, VAI was able to reliably predict remission in persons with BMI < 35 kg/m2[71]. The estimates of visceral adiposity might be potentially better pointers of insulin resistance than anthropometric parameters in Asians with lower BMI and hence may more reliably predict probability of remission. Further validation of this hypothesis is however needed in larger and long-term studies.

**Scoring systems for remission:** Several scoring systems have been proposed as predictors of DM remission following metabolic surgery. The ABCD scoring system devised by Lee *et al*[72], incorporated age at surgery (A), baseline BMI (B), C-peptide level (C), and duration of DM (D). The DiaRem score was suggested by Still *et al*[73], and includes age, insulin use, HbA1C level, and type of anti-diabetic medication. The IMS score categorizes patients into three stages of severity based on the preoperative number of DM medications, insulin use, duration of DM, and glycemic control (HbA1c < 7%). The system also provides recommendations on the type of procedure (RYGB or LSG) for each severity stage based on each procedure's efficacy and risk-benefit ratio[74]. Though one analysis suggested that the ABCD score had better predictive efficacy as compared to the IMS score and DiaRem score, the committee does not acknowledge one scoring system's superiority above the other in the absence of evidence from large multicenter studies[75,76].ACF scoring system is another recently reported model that utilizes the three variables: age, C-peptide area under curve, and FPG to predict remission[77].

**PREOPERATIVE ASSESSMENT AND OPTIMIZATION OF GLYCEMIC STATUS**

***Recommendation 10***

The initial preoperative assessment should include a comprehensive medical, psychosocial and drug history, along with physical examination. Appropriate laboratory tests should be done to assess glycemic control. These tests should include FPG, postprandial glucose, and HbA1c in all cases and self-monitoring of blood glucose and/or continuous glucose monitoring system in selected cases. Estimation of serum C-peptide should be done to assess the scope for the remission of DM (E).

***Recommendation 11***

A glycemic target of HbA1c < 7% before surgery is a reasonable goal. Medical nutrition therapy, physical exercise, and pharmacotherapy should be optimally integrated to attain that goal (E). Pharmacological agents known to induce weight loss, such as sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists, should be considered as part of the treatment armamentarium whenever feasible. Drugs known to cause weight gain, such as sulfonylureas and thiazolidinediones, should be avoided as long-term therapeutic strategy if possible. The perioperative risks of deranged glycemic control *vs* benefits of early metabolic surgery have to be assessed on a case-to-case basis if glycemic control cannot be attained preoperatively despite optimal medical treatment. If a strategy of restricting calories with meal replacement therapy is employed in the preoperative weeks, the anti-diabetic medications would need to be reduced to prevent hypoglycemia (E).

***Recommendation 12***

After admission, most non-insulin based therapies should be stopped, and the patient should be transitioned to insulin as per institutional practice. Severe degrees of hyperglycemia will require intravenous insulin infusion. Target glucose of 100 to 180 mg/dL (5.5-10 mmol/L) is acceptable in the perioperative period (E).

***Discussion***

**Glycemic target:** Table 5summarizes therecommended evaluation in individuals with DM before metabolic surgery. Inadequate glycemic control in the preoperative period is associated with increased 1-year mortality, wound complications, infective complications, and extended hospital stay[78-81]. Pre-surgery deranged glycemic status and medication usage, including insulin and the number of drugs required to achieve euglycemia, negatively correlate with the chance of long-term remission of DM following metabolic surgery[61,73,74,76]. Only a few studies, however, have specifically assessed the role of preoperative glycemic control to short-term postoperative outcomes. The clinical practice guidelines by the AACE/TOS/ASMBS/OMA/ASA suggest an HbA1C target of 6.5% to 7.0% or less before surgery, and peri-procedure blood glucose levels of 80 to 180 mg/dL (4.4–10 mmol/L). In the presence of advanced microvascular or macrovascular complications, or comorbidities, or long duration of DM, they recommended an HbA1C target between 7% and 8%[33]. An interprofessional bariatric glycemic optimization clinic-based study analyzing 70 patients, was able to lower HbA1C from a mean level of 9.0% ± 1.2% to ≤ 7.5% in 75% of patients before surgery in 5 mo[82]. In a retrospective review of 468 patients who had undergone RYGB, higher pre-surgery HbA1c (> 6.5%) was associated with an increased chance of postoperative hyperglycemia. These patients also had a greater risk of wound infection and acute renal failure[83].

A RCT of 34 patients with a mean A1C of 10% at baseline, did not show any differences in the length of stay or surgical complications in the two arms of optimized (HbA1c-8.4%) *vs* non-optimized (HbA1c–9.7%) glycemic therapy. This was the only RCT that attempted to identify the impact of two different glycemic strategies, but had shortcomings such as a narrow margin between achieved HbA1c (> 8% in both arms) and small sample size. Another drawback was both the arms were offered the same dietary and glycemic interventions for the preceding 2 wk immediately before surgery[84]. A target glucose of 100 to 180 mg/dL (5.5-10 mmol/L) should be the perioperative period goal[85].The approach to achieve this target should be guided by institutional policy. Intravenous insulin as per protocol should be administered in cases of severe hyperglycemia[86].

Pre-operative calorie restriction for two to four weeks has been conventionally practiced in many bariatric centers. Though the methods have been very variable, these practices might warrant adjustment of anti-diabetic medications[87,88].

**PREOPERATIVE ASSESSMENT AND OPTIMIZATION OF CARDIOVASCULAR STATUS**

***Recommendation 13***

The target blood pressure (measured by appropriately sized cuff) before surgery is < 140/90 mmHg. Angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs), thiazide diuretics, or dihydropyridine calcium channel blockers (CCBs) are the preferred agents, and multiple drug classes are usually necessary to accomplish blood pressure goals (a combination of ACE inhibitors and ARBs to be avoided) (A). Patients already on beta-blocker should be continued on the same. Initiating a beta-blocker in the preoperative phase is controversial and should be individualized after estimating risk *vs* benefit (B).

***Recommendation 14***

A fastinglipid profile should be done in all patients. Lipid-lowering therapy as per current recommendations should be initiated (A).

***Recommendation 15***

A resting 12-lead electrocardiogram (ECG) should be obtained before metabolic surgery. The ECG, other than serving as a baseline for comparison in any subsequent cardiac adverse events, can provide clues regarding left ventricular hypertrophy, possible ischemia (Q waves, ST-segment depression), and bundle branch blocks, arrhythmia, and QTc prolongation (B).

***Recommendation 16***

Assessment of left ventricular function by resting transthoracic echocardiography should be undertaken in patients with unexplained dyspnea, and known cases of heart failure, especially with recent changes in clinical status. Right ventricular hypertrophy in echocardiography can be indicative of pulmonary hypertension. Valvular abnormalities and other structural lesions can also be detected by echocardiography (B).

***Recommendation 17***

A cardiovascular risk assessment is recommended before surgery. Several risk prediction models to assess perioperative cardiac risk have been suggested and validated in obese individuals. Individuals at an elevated risk (1% or more) of a major adverse cardiac event (MACE) during the perioperative period and having a poor (< 4 metabolic equivalents [METs]) or unknown functional capacity should undergo further risk stratification with exercise or pharmacological stress echocardiography, or radionuclide myocardial perfusion imaging to assess for myocardial ischemia. Individuals with a normal stress test can proceed to surgery, whereas those with an abnormal result should be managed according to the current clinical practice guidelines. Those with underlying cardiac abnormalities should undergo a formal cardiology consultation before surgery (E).

***Discussion***

**Blood pressure and lipids:** The target blood pressure recommended by ADA in individuals with DM is less than 140/90 mmHg. Lower targets such as 130/80 can be pursued for individuals at high risk of cardiovascular disease if that goal can be attained by reasonable therapeutic means[89]. Meta-analyses have demonstrated equivalent efficacy of ACE inhibitors or ARBs (to be avoided together), thiazide diuretics, or dihydropyridine CCBs in reducing cardiovascular outcomes, and any of these can be used as a first-line agent[90,91]. Most individuals, however, will require multiple agents for normalization of blood pressure[89]. As per the American College of Cardiology (ACC)/American Heart Association (AHA) recommendations published in 2014, beta-blockers should be continued in those who have been receiving them for long duration. The risks and benefits of initiating beta-blockers before surgery should be individualized according to the clinical situation[92]. Lipid-lowering therapy should be initiated as per the current practice guidelines[93].

**12-lead ECG and echocardiography:** A 12-lead ECG should be obtained before metabolic surgery. It acts as a reference against which the postoperative changes can be compared. Also, arrhythmias, pathological Q-waves, LV hypertrophy, ST depression, QTc interval prolongation, and bundle-branch blocks can provide useful clues, but the prognostic utility of an ECG to predict the perioperative cardiovascular outcome is limited[92,94]. The ACC/AHA guidelines recommend assessment of LV function by echocardiography in patients with dyspnea of unknown origin and for patients with heart failure with worsening dyspnea or recent change in clinical status[92].

**Cardiac risk prediction models:** Several risk prediction models have been proposed to estimate the perioperative risk of MACE in individuals undergoing non-cardiac surgery[95-98]. The most commonly used scoring system is the Revised Cardiac Risk Index, which incorporates the following variables as predictors of perioperative cardiac risk: high-risk surgery, history of ischemic heart disease, history of CHF, creatinine > 2 mg/dL, cerebrovascular disease, and DM requiring insulin. The 30 d risk of death, myocardial ischemia, or cardiac arrest is 0.4% if none of the factors are present. The presence of one predictor pertains to a risk of 0.9% for these events, two predictors carry a 6.6% risk, and three or more factors correlate with an 11% risk[99]. Bariatric surgery itself is considered as an intermediate to high-risk non-cardiac surgery, and the presence of any other additional factor will warrant further assessment[100].

Scoring systems such as obesity surgery mortality risk score (OS-MRS) for bariatric surgery have also been validated. The OS-MRS assigns one point each to the following five risk factors: age ≥ 45 years, male sex, BMI ≥ 50 kg/m2, hypertension, and known risk factors for pulmonary embolism (previous thrombosis, pulmonary embolism, inferior vena cava filter *in situ*, a history of right heart failure or pulmonary hypertension and obesity-hypoventilation syndrome)[101]. The mortality rate in class A (score 0 to 1) was 0.26%, in class B (score 2 or 3) was 1.33%, and in class C (score 4 or 5) was 4.34%[102]. Other methods that have been used to stratify surgical risk in obese patients include the Longitudinal Assessment of Bariatric Surgery consortium risk stratification system, the metabolic acuity score, and a nomogram for assessing surgical complications in bariatric surgery[103-105]. Our committee recommends individualized evaluation of candidates as per recommended practices before undergoing surgery, if they have an estimated (by general or obesity specific scoring system) perioperative mortality or MACE risk ≥ 1%. Further studies are required to validate the optimal prediction model to stratify perioperative risk in individuals undergoing metabolic surgery for obesity and DM.

**Approach for cardiovascular evaluation and management**: Our committee endorses the approach suggested in the 2014 ACC/AHA guideline of perioperative cardiovascular evaluation and management of patients undergoing non-cardiac surgery. In all cases at elevated risk (estimated perioperative mortality risk or MACE risk ≥ 1%), assessment of the functional status of the patient should be undertaken. In case the patient can perform ≥ 4 METs of activity (can walk up a flight of steps or a hill or walk on level ground at 3 to 4 mph), additional tests are usually not recommended. For those whose functional capacity is lower or unknown, additional stress testing may be indicated if it will influence perioperative care[92]. Assessment of functional capacity might not be possible in many patients with obesity for unrelated reasons such as osteoarthritis. Pharmacological stress testing may be warranted in such cases. Both obesity and DM are substantial risk factors for cardiovascular disease. In many situations, the strategy to assess cardiac risk has to be individualized in consultation with the cardiologist, specifically when proper assessment of the patient’s functional status cannot be performed. Those with pre-existing cardiological disease must undergo a formal cardiology consultation before metabolic surgery[33].

**PREOPERATIVE EVALUATION AND OPTIMIZATION OF PULMONARY FUNCTION**

***Recommendation 18***

A structured tobacco cessation program should be employed for patients who smoke cigarettes before undergoing surgery (E).

***Recommendation 19***

Pulmonary function test (PFT) or spirometry is not routinely indicated. Definitive evidence that PFT can predict postoperative pulmonary complications is lacking, and the testing should be restricted for those with an intrinsic pulmonary disease where the findings would alter the management (E).

***Recommendation 20***

UntreatedOSA increases the risk of perioperative complications. Considering the high prevalence of undiagnosed OSA in severely obese individuals, screening for OSA by a clinical scoring tool such as the STOP-BANG questionnaire (or Berlin questionnaire) should be performed. The gold standard test to confirm the diagnosis of OSA in suspected cases is overnight polysomnography (PSG). The use of continuous positive airway pressure (CPAP) in the preoperative period for treatment of moderate to severe OSA is recommended to reduce the risk of perioperative pulmonary complications (B).

***Recommendation 21***

OHS often coexist with OSA in severely obese individuals, and the presence of OHS should be ruled out in all patients diagnosed to have OSA. Arterial blood gas analysis for PaCO2 estimation along with measurement of venous HCO3- (cut off 27 mmol/L) can be used to establish the diagnosis of OHS. Institution of positive airway pressure therapy and lifestyle modification is recommended for patients diagnosed to have OHS (B).

***Recommendation 22***

A risk assessment for possibility of development of venous thromboembolism (VTE) in the perioperative period should be undertaken. The possible risk factors for VTE include prior VTE, higher BMI, age, gender, immobility, use of hormone therapy, OHS, pulmonary hypertension, venous stasis disease, operative time, and procedure type and approach (B). There are insufficient data to recommend a uniform strategy to prevent VTE complications. The standard recommendations are mechanical compression devices with early ambulation in addition to chemoprophylaxis (B). There is inadequate evidence to recommend prophylactic placement of inferior vena cava (IVC) filters to prevent pulmonary embolism and it should be applied under very selected circumstances (E).

***Discussion***

**Smoking and tobacco cessation:** Smoking increases the risk of postoperative morbidity following metabolic surgery. Smoking is associated with an increased risk of organ space infection, prolonged intubation, reintubation, pneumonia, sepsis, shock, and longer length of hospital stay[106]. In a recent systemic review, smoking during a year before undergoing surgery, was an independent risk factor for higher 30 d mortality and major postoperative complications, particularly wound and pulmonary complications[107].Perioperative tobacco cessation reduces the chance of surgery-related morbidities[108]. A structured program is more effective than general advice[109].

**PFT:** The utility of PFT to predict postoperative complications is uncertain. In a prospective study of 485 patients who underwent laparoscopic metabolic surgery, abnormal spirometry in the preoperative period was associated with a three-fold risk of postoperative complications[110].In a retrospective analysis of 602 patients, abnormal spirometry before surgery was shown to correlate with the risk of postoperative pulmonary complications only in those with OSA[111]. In another retrospective cohort of 146 severely obese BPD candidates, the logistic regression model suggested that the preoperative PFT could not predict respiratory complications after surgery[112].

**OSA:** OSA is a common comorbidity of severe obesity, with the reported prevalence of close to 80% in patients planned for metabolic surgery[113-116]. Untreated OSA increases the risk of postoperative complications[117,118]. We endorse the consensus guidelines by de Raaff *et al*[119]. regarding screening and management of OSA before metabolic surgery. A clinical scoring tool to screen for OSA should be used in all patients planned for surgery. The STOP-Bang Questionnaire’s sensitivity to detect mild and severe OSA was highest, while the STOP Questionnaire had the highest sensitivity to predict moderate OSA[120]. Berlin questionnaire can also be used to screen, but Epworth Sleepiness Scale is not recommended[119]. Overnight PSG is the gold standard to confirm the diagnosis of OSA. Simpler portable devices that can analyze a limited range of variables, known as type 3 portable sleep monitoring (as per definition of the American Academy of Sleep Medicine) can be used if there is a high pretest probability for moderate to severe OSA[119,121]. CPAP usage in the perioperative phase decreases the chance of pulmonary complications and is recommended for treatment of moderate to severe OSA[119,122].

**OHS:** OHS is defined as the triad of obesity (BMI > 30 kg/m2), daytime hypoventilation, and sleep-disordered breathing in the absence of an alternative neuromuscular, mechanical, or metabolic explanation for hypoventilation. The prevalence of OHS is 20%-30% among individuals with obesity and OSA[123]. In a recently published study, the prevalence of OHS in a bariatric cohort of 1718 patients was 68%[124]. OHS should be ruled out in patients diagnosed with OSA by measuring serum HCO3- or arterial blood gas analysis. Elevated serum HCO3- (> 27 mmol/L) and/or increased PaCO2 (> 45 mmHg) are indicative of OHS[125]. Institution of positive airway pressure therapy along with lifestyle modification is recommended for patients diagnosed to have OHS[119,126].

**VTE:** Individuals with obesity are at an increased risk of VTE, though the overall rate following metabolic surgery has been reported to be < 1%[127-129]. A preoperative risk assessment model to stratify candidate by VTE risk was devised by Fink *et al*[130] using the following variables: procedure type, patient history of VTE, male sex, BMI, age, and operative time > 3 h. By this scheme, 97% were classified into low-risk groups with a predicted VTE risk of < 1%. The medium-risk group had an estimated VTE risk of 1%-4%, and the high-risk group had > 4% - 30 d VTE event rate[130]. Other tools to assess DVT risk have also been proposed[131]. Further risk factors for VTE include immobility, known hypercoagulable condition, OHS, pulmonary hypertension, venous stasis disease, hormonal therapy, and transfusion[129,130,132,133]. We endorse the ASMBS recommendations for VTE prophylaxis in those undergoing metabolic surgery. All candidates are at moderate to high risk of VTE and require mechanical prophylaxis and early ambulation. Additional chemoprophylaxis with low molecular weight heparin should be considered unless contraindications arise from bleeding tendency or other causes[134]. Placement of IVC filter is not routinely indicated[134,135].

**GASTROINTESTINAL EVALUATION**

***Recommendation 23***

Preoperative upper gastrointestinal (GI) endoscopy can be considered before performing metabolic surgery, though conclusive evidence supporting its routine usage is lacking (C). Because of worsening of previous GERD and risk of development of new-onset GERD on long-term follow-up after LSG, it is recommended that upper GI endoscopy should be performed in candidates for LSG (B).

***Recommendation 24***

There is inadequate evidence to supportor refute in favor of routinely performing tests to detect and treat *Helicobacter pylori* during preoperative evaluation.

***Discussion***

**Upper gastrointestinal endoscopy:** There is a lack of consensus regarding the utility of routine upper GI endoscopy before surgery[33,136]. Two meta-analyses explored the benefits of preoperative endoscopy[137,138]. In the meta-analysis by Parikh *et al*[137] (*n* = 6112), endoscopic findings were normal in the majority (92.4%), and only 7.6% had abnormalities that delayed or altered surgery[137]. In the meta-analysis by Bennett *et al*[138] (*n* = 12261), endoscopic findings necessitated a change in surgical management in 7.8% and medical management in 2.5% (after excluding *H. pylori*). The authors concluded that preoperative upper GI endoscopy in average-risk, asymptomatic individuals should be considered optional as the proportion of endoscopies with findings that resulted in alteration in management was low[138]. In two recent studies, treatment strategy was changed only in a small percentage of patients based on endoscopic findings[139,140].

**GERD:** GERD is increasingly recognized as a long-term complication of LSG and has been considered a relative contraindication[141]. A meta-analysis evaluating the outcome of 10718 patients after LSG found that 19% had increased symptoms and 23% developed new-onset GERD after surgery. The long-term prevalence of esophagitis was 28%, and that of Barrett's esophagus (BE) was 8%[142]. A significant percentage of patients detected to have GERD on endoscopy are asymptomatic and thus were diagnosed only on routine screening[143]. The prevalence of GERD in bariatric candidates was not different between those with or without DM[144]. Our panel recommends upper GI endoscopy in patients planned for LSG to rule out symptomatic and asymptomatic GERD. Dedicated studies to assess the evolution of GERD after LSG are required.

**Gastric lesions:** A recent meta-analysis scrutinized gastric lesions that requires subsequent endoscopic monitoring after surgery. Atrophic gastritis was detected in 2.64%, and intestinal metaplasia in 2.7%[145]. Lesions such as atrophic gastritis, intestinal metaplasia, or gastrointestinal stromal tumor mandate endoscopic monitoring post-surgery. LSG should be considered in preference to RYGB in the presence of these conditions. However, the prevalence of these lesions is negligible, and it is not clear whether routine preoperative endoscopy will have a significant role.

***H. pylori*:** There is a lack of consensus regarding the utility of detecting and eradicating *H. pylori* before metabolic surgery[136]. A meta-analysis of seven studies with 255435 patients revealed that rates of bleeding, leak, length of hospital stay, and weight loss were similar between *H. pylori* positive and negative groups. Marginal ulceration following RYGB was the only outcome that correlated with its presence[146]. Another meta-analysis demonstrated that eradication of *H. pylori* decreased the risk of marginal ulceration, but the rates still remained high (1.5%-18.8% following eradication *vs* 0.5%-31.2% in the non-eradicated group). The authors acknowledged the methodological limitation in many of the studies included in the meta-analysis[147]. Efficacy of *H. pylori* treatment in preventing complications (especially after RYGB) needs further assessment in well-designed trials.

**HEPATIC EVALUATION**

***Recommendation 25***

Allcandidates for surgery should be investigated for NAFLD. There is no consensus about the methodology for diagnosis of NAFLD. Liver function test (LFT) should be performed routinely before surgery. Abdominal ultrasonography (USG) is recommended if LFT is deranged or symptomatic biliary disorder is suspected. Evidence to support routine imaging of the liver during preoperative evaluation is lacking (E).

***Recommendation 26***

Several noninvasive scoring systems have been proposed to assess the risk of fibrosis in the bariatric population. However, more evidence is required before a particular strategy can be recommended for clinical application. Liver elastography can be considered in those with suspected NAFLD, but diagnostic accuracy is limited in severe obesity. The gold standard for diagnosing NAFLD is intraoperative liver biopsy, but the clinical strategy to identify patients who will benefit from the biopsy has to be formulated through well-structured studies (E).

***Discussion***

NAFLD is present in up to 81% of patients undergoing metabolic surgery.The global prevalence of NAFLD and nonalcoholic steatohepatitis (NASH) in T2DM were reported to be 55.5% (95%CI: 47.3-63.7) and 37.3% (95%CI: 24.7-50.0) respectively in a meta-analysis[150]. The therapeutic options for NAFLD are limited and metabolic surgery is the only modality that has consistently demonstrated benefit[149,151–153]. However the modalities and clinical strategy to diagnose and follow these patients are not clearly defined[154–157]. Even though the sensitivity of USG to detect NAFLD is high, but its low specificity in obese individuals remains a drawback[148,158]. The noninvasive fibrosis scores that have been commonly studied in the bariatric population include NASH clinical scoring system NCS[159], aspartate aminotransferase to platelet ratio index[160], fibrosis-4 index[161], NAFLD fibrosis score[162], BARD score[163], and Forns index[164]. The scoring systems were able to predict fibrosis in some but not in all studies[155,165,166]. Their usefulness in detecting fibrosis before surgery requires validation in more extensive studies. Transient elastography, two-dimensional shear wave elastography, and acoustic radiation force impulse shear wave imaging reliably predicted advanced fibrosis in bariatric candidates in small studies[167–169]. Three-dimensional magnetic resonance elastography is a promising modality to detect NASH and has demonstrated a sensitivity of 67% and specificity of 80%[170]. Intraoperative liver biopsy remains the gold standard for the diagnosis of NASH in bariatric candidates. However, it is associated with a small increase in the rate of complications[149]. The morphology of the liver can be visualized during surgery and can provide a clue regarding necessity for biopsy[158].

Obesity and DM are associated with high prevalence of NAFLD, often with significant fibrosis[151,158]. Metabolic surgery does improve outcomes related to NAFLD in a significant proportion of patients[152–154]. Post-surgery hepatology follow-up to assess the risk of progression to cirrhosis is recommended in these groups. None of the imaging modalities and noninvasive scoring systems have convincing evidence to support their routine clinical application. Intraoperative liver biopsy provides a reliable way to diagnose and assess the severity of NAFLD, but it is currently unclear what criteria should be applied to identify patients who will benefit from biopsy.

**ASSESSMENT OF RENAL FUNCTION, ELECTROLYTES, AND URIC ACID**

***Recommendation 27***

Individuals with DM planned for metabolic surgery should undergo estimation of spot urinary albumin-creatinine ratio (ACR). Serum creatinine measurement along with the assessment of estimated glomerular filtration rate (eGFR) is also recommended (E).

***Recommendation 28***

In patients on diuretics, ACE inhibitors, or ARBs, serum potassium levels should be obtained. Studies to support the measurement of electrolytes on a routine basis before surgery are lacking. Clinical factors, especially the presence of chronic kidney disease (CKD) and drug history, usually indicate whether assessment of other electrolytes is necessary (E).

***Recommendation 29***

Serum uric acid should be measured in individuals with a history of gout, and prophylactic treatment of acute gouty arthritis should be considered in these patients (E).

***Discussion***

**Calculation of eGFR in severe obesity:** Both DM and obesity are leading causes of the development and progression of CKD[171–173]. The ADA recommends estimating urinary ACR and serum creatinine (along with eGFR) in individuals with DM annually. Serum potassium should be measured in individuals receiving ACE inhibitors, ARBs, or diuretics[174]. Calculation of eGFR is usually done using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula[175]. The CKD-EPI formula using creatinine tends to overestimate eGFR in bariatric patients both before and after surgery, while the cystatin C CKD-EPI equation tends to underestimate it[176]. The errors in using the standard equations in severely obese subjects arise from changes in the body surface area (error of indexing), alteration in serum creatinine and cystatin C levels, and obesity-induced glomerular hyperfiltration[177]. The combined equation CKD-EPIcreat-cyst using serum creatinine and cystatin C values reliably predicted eGFR in severe obesity both before and after surgery but further validation in larger cohorts is needed[176,178,179].

**Reno-protective effects of metabolic surgery:** Metabolic surgery is a promising reno-protective strategy in obesity, even without DM[180,181]. In a study of 737 subjects, remission of DM 5 years after surgery was associated with a lower risk of moderate or severe albuminuria but did not result in stabilization of eGFR[182]. A meta-analysis of 23 cohort studies with 3015 subjects reported a significant fall in serum creatinine level and proteinuria after surgery. The subgroup of patients with hyperfiltration and CKD also showed improvement in eGFR after 6 mo[183].

**Precautions in CKD:** The weight-lowering response following surgery and chances of DM remission may be diminished in CKD stages 4 and 5[182,184,185]. Decreased eGFR before metabolic surgery also correlated with a higher chance of surgical site complications, infections, cardiovascular events, and clotting disorders in the postoperative period. However, the overall number of adverse events across all stages were low[186,187].

**Renal stone disease:** Another renal adverse event with the potential for causing acute and chronic kidney damage is hyperoxaluria occurring after malabsorptive procedures[188–190]. A meta-analysis of 11 observational studies demonstrated that RYGB increases the risk of hyperoxaluria and renal stone formation[190]. Age, history of urinary tract infection, and renal stone disease correlate with a higher chance of new stone formation after surgery[191,192]. History of nephrolithiasis mandates close urological follow-up post-surgery.

**Hyperuricemia:** Obesity and hyperuricemia are closely interrelated and often coexist[193,194]. A meta-analysis of 20 studies with 5233 participants reported that the mean serum uric acid before surgery was 6.5 mg/dL. Metabolic surgery was followed by a transient elevation in serum uric acid in the first month, followed by a fall from the third month. The long-term incidence of gout was decreased[195]. There is a higher possibility of acute gout in the postoperative phase, and high-risk patients should be considered for prophylactic uric acid lowering medications before surgery[196,197].

**NUTRITIONAL ASSESSMENT AND OPTIMIZATION**

***Recommendation 30***

A preoperative nutritional assessment by a dietitian with expertise in bariatric counselling should be considered. Current macronutrient and micronutrient intake pattern should be evaluated. Medical nutrition therapy to optimize glycemic control before surgery should be reinforced. The candidate should be educated about dietary and lifestyle changes required after the surgery (E).

***Recommendation 31***

The low-grade chronic inflammation associated with obesity, destabilizes the iron homeostasis and predisposes to iron deficiency, and decreases iron bioavailability. A complete blood count, serum ferritin, serum iron, total iron-binding capacity, and transferrin saturation (TS) is recommended during preoperative work-up. In presence of chronic inflammation denoted by serum CRP > 8 mg/L, serum ferritin loses specificity as an indicator of iron deficiency, and other markers like serum iron and TS should be used to define iron deficiency. Iron deficiency should be treated by oral iron supplementation. Parenteral iron should be considered if oral treatment is not tolerated or if early correction is needed (B).

***Recommendation 32***

Estimation of vitamin B12 and folate levels are recommended during pre-operative work up. In low-normal cases with high index of suspicion, measurement of serum methylmalonic acid and homocysteine levels can be considered. Vitamin B12 deficiency should be corrected by parenteral administration in symptomatic cases, whereas oral therapy is sufficient in asymptomatic individuals. Folic acid deficiency should be treated by oral supplements (B).

***Recommendation 33***

Vitamin Ddeficiency (VDD) is prevalent in individuals with obesity. Estimation of serum calcium and 25-hydroxyvitamin D (25(OH)D) is recommended before surgery. Serum parathyroid hormone (PTH) assessment can be considered in patients with VDD. Vitamin D should be replaced orally if VDD is present (B).

***Recommendation 34***

Estimation of copper, zinc, and selenium; and fat-soluble vitamins such as vitamin A, E and K can be considered before malabsorptive procedures.

***Discussion***

**Nutritional counselling:** A meta-analysis of three RCTs revealed that there was inadequate data to support or refute preoperative nutritional counselling[198]. A review on the same topic suggested that preoperative medical weight management strategies failed to achieve consistent benefits probably because of lack of dedicated trials[199]. Even then, nutritional counselling is safe, requires minimal resources, helps to create a rapport with the bariatric team and prepares the patient for necessary lifestyle modifications required around and after the surgery. It is an important adjunct to comprehensive bariatric care and is recommended by most guidelines[33,136,200].

**Anemia and iron deficiency:** Micronutrientdeficiency is common among candidates of metabolic surgery and worsens further during follow-up[201,202]. The prevalence of anemia and iron deficiency ranges from 6.1%-22% and 5.7%-24% respectively, in metabolic surgery candidates[203–207]. Low-grade inflammation associated with obesity can interfere with the intestinal absorption and iron utilization in the bone marrow[208,209]. Iron deficiency is characterized by serum ferritin < 30 ng/mL. CRP concentration above 8 mg/L is suggestive of overt inflammation, while levels between 3 to 8 mg/L conventionally signify subclinical inflammation[210]. In the presence of CRP > 8 mg/L, serum ferritin up to a concentration of 100 ng/mL indicates iron deficiency[211]. Serum CRP > 8 mg/L, serum ferritin > 100 ng/mL, and TS < 20% denotes anemia of chronic disease[212].

CRP > 5 mg/L, often associated with mild inflammation present in obesity, can alter iron metabolism[212,213]. Laboratory assessment of iron deficiency should be done at least 1 mo before surgery so that adequate time for replenishment of stores is available[214]. Iron supplementation is usually done through oral formulations, but parenteral preparations may be necessary if oral iron is not tolerated or if quick response is required[213,214]. Parenteral iron therapy has the advantages of rapid replenishment of iron stores before surgery and overcomes the uncertainty of absorption, compliance, and tolerability associated with oral therapy[214]. Systemic studies that investigate the benefits of parenteral iron therapy before metabolic surgery are required.

**Vitamin B12 and folic acid deficiency:** Vitamin B12 deficiency has been reported in up to 23% of candidates of metabolic surgery[206,215–218]. Additionally, metformin is known to cause deficiency of vitamin B12 in T2DM[219,220]. Folic acid deficiency is common among patients planned for metabolic surgery and is reported in up to 28% of cases[217,221,222]. Estimation of serum vitamin B12 and folate levels are recommended before surgery[33,223]. Low vitamin B12 should be treated by parenteral administration in megaloblastic anemia, neuropathy, or in presence of other deficiency symptoms[33,200,223–225]. A systemic review by Smelt *et al*[226] suggested that daily oral administration of 350 μg of vitamin B12 corrects low levels in most cases. The guideline by AACE/TOS/ASMBS/OMA/ASA suggests oral vitamin B12 at a dose between 350 to 1000 μg every day. Alternatively it can be administered by nasal route[33]. Oral folic acid supplementation should be initiated to correct deficiency[33,223]. Measurement of serum methylmalonic acid and homocysteine to assess for functional deficiency can be considered in cases with low-normal levels but high-index of suspicion, though such a strategy has not been validated[33,224,227,228].

**VDD:** Systematic reviews and meta-analyses have suggested that VDD is common in obese individuals and candidates of metabolic surgery[229–232]. Most guidelines recommend routine measurement of serum calcium and 25(OH)D before surgery[33,201,223,224]. Estimation of serum PTH, serum or urinary N-telopeptide, bone-specific alkaline phosphatase, and bone mineral density can be considered if osteoporosis is suspected (especially in postmenopausal women)[224,233]. VDD should be corrected before surgery but there is no consensus on the exact dosage with guidelines recommending between 3000 IU daily to 50000 IU one to three times weekly[234].

**Other trace elements**: Malabsorptive procedures can cause deficiency of trace elements like zinc, copper and selenium and fat soluble vitamins (vitamins A, D, and E)[201,235–237]. Some of the guidelines suggest their preoperative measurement[33,223,224].

**ENDOCRINE AND REPRODUCTIVE FUNCTION ASSESSMENT**

***Recommendation 35***

Case-by-case decision depending on the clinical profile should be undertaken to rule out the presence of endocrine disorders (E). Thyroid function test (TFT) should be ordered in those with past history of thyroid disorders. Medications for thyroid should be adjusted to ensure that the patient is euthyroid before surgery. In the absence of history, TFT is indicated if there is clinical suspicion of hypothyroidism or presence of goiter (E). If endogenous Cushing’s syndrome is suspected, one or more of the following tests should be done: 1-mg overnight dexamethasone suppression test (ONDST), 24-h urinary free cortisol, or 11-pm salivary cortisol (E).

***Recommendation 36***

Women in reproductive age group scheduled to undergo metabolic surgery should avoid pregnancy. The possibility of improvement in fertility after surgery should be discussed. It is recommended to avoid pregnancy for 12-18 mo following surgery (B). Oral contraceptives or hormone replacement therapy should be discontinued 1 mo before surgery to decrease the risk of thromboembolism (E). If there is clinical suspicion of PCOS, total and bioavailable testosterone and USG of the pelvis assist in establishing the diagnosis. Hypogonadotropic hypogonadism (HH) is commonly reported in males with DM and obesity. Luteinizing hormone, follicle-stimulating hormone, and testosterone total should be measured in males if HH is suspected (E).

***Recommendation 37***

A decision to evaluate for monogenic or syndromic causes of obesity should be individualized (E).

***Discussion***

**Thyroid disorders:** Theguideline by AACE/TOS/ASMBS/OMA/ASA recommends that patients known to have hypothyroidism should undergo TFT before surgery, and thyroxine dose should be adjusted to achieve euthyroidism[33]. A meta-analysis of 24 studies demonstrated that metabolic surgery decreased the thyroid stimulating hormone, free triiodothyronine (FT3), and total triiodothyronine levels. Additionally, thyroxine requirement was reduced in overt and subclinical hypothyroidism[238]. Preoperative FT3 above reference range and thyroid autoimmune status in euthyroid persons was shown to correlate with weight loss after metabolic surgery in small studies[239,240]. Larger studies are required to corroborate these findings. There is also a paucity of evidence to support routine preoperative evaluation of thyroid status in patients before surgery, but many insurance providers advocate it. Thyroid profile should be obtained if there are suggestive clinical features or if a goiter is present.

**Cushing’s syndrome:** Cushing’s syndrome has rarely been reported in patients undergoing metabolic surgery and should be ruled out by ONDST, 24-h urinary free cortisol, or 11-pm salivary cortisol if there is clinical suspicion[241–245]. If the screening tests are positive further evaluation is required.

**Pregnancy and fertility:** Most current guidelines recommend avoiding pregnancy if metabolic surgery is scheduled for a period of 12 to 18 mo after surgery[33,223,246]. A meta-analysis of 33 studies analyzing 14880 pregnancies after metabolic surgery indicated that pregnancies after restrictive surgeries tend to have a better perinatal outcome than after malabsorptive procedures[247]. In another meta-analysis, malabsorptive procedures as compared to restrictive procedures, were shown to increase the risk for small-for-gestational-age infants (*P* = 0.0466) but decreased the chance of large-for-gestational-age infants (*P* < 0.0001)[248]. Fertility rates in obese women with infertility were investigated in the meta-analysis by Milone *et al*[249]. Spontaneous pregnancy occurred in 58% of the 589 infertile women after surgery. Women in the reproductive age group should be counseled about the possibility of improvement in fertility after surgery, and contraceptive choices should be considered. The bioavailability of oral contraceptives can be decreased after malabsorptive procedures, and alternative contraception methods should figure in the conversation[250]. Estrogen preparations increase the risk of thromboembolism and should be discontinued 1 mo before surgery[33,246].

**PCOS:** Three meta-analyses have analyzed PCOS in relation to metabolic surgery[251–253]. PCOS was reported to be present in 36%-45.6% of women before surgery. Resolution of PCOS occurred in the majority of the cases after surgery[251,252].

**Male hypogonadism:** One of the meta-analysis reported the prevalence of male obesity-associated secondary hypogonadism to be 64%, with resolution occurring in 87% of patients following surgery[252]. A review demonstrated that metabolic surgery was more effective than a low-calorie diet (LCD) in improving free and total testosterone in obesity-associated HH[254]. Additionally, T2DM is also associated with low testosterone levels[255]. In the presence of suggestive clinical features, we recommend to rule out PCOS in females and HH in males during preoperative evaluation.

**Monogenic or syndromic obesity:** A genetic cause (monogenic or polygenic) is responsible for 5%-10% of early-onset severe obesity[256,257]. Non-syndromic monogenic obesity usually results from the affection of the leptin-melanocortin pathway[258,259]. Syndromic obesity refers to childhood-onset severe obesity associated with dysmorphism and neurodevelopmental and systemic malformations[260]. The common variants are Prader Willi, Bardet–Biedl, Cohen, and Alström syndromes[261]. There is limited evidence to support the role of metabolic surgery in genetic and syndromic obesity at present[256]. A cohort of 133 obese patients with monogenic obesity present among 8.4% of the candidates, were followed up 6 years after LSG. Subjects with monogenic obesity had less short and long-term weight loss than those who did not carry any mutation[262]. Similarly, metabolic surgery was ineffective in causing long-term weight loss in five patients with Prader Willi syndrome over a 10-year period[263]. The evidence to routinely screen for genetic causes in patients undergoing metabolic surgery is inadequate.

**PSYCHOLOGICAL ASSESSMENT**

***Recommendation 38***

Patients planned for metabolic surgery should be considered for a behavioral and psychosocial evaluation by a psychiatrist or psychologist with expertise in bariatric patients. Factors that can adversely affect the long-term outcome after metabolic surgery should be addressed (B).

***Discussion***

The health-related quality of life in severe obesityis worse in comparison to non-obese counterparts[264]. The psychiatric comorbidities in these patients are also high[265]. A formal psychological evaluation is suggested in the current guidelines[33,136,266]. A meta-analysis assessing preoperative mental health in 65363 patients before surgery, reported depression to be present in 19% and binge eating disorder in 17%. These conditions, however, did not consistently affect weight loss after surgery. On the other hand, moderate-quality evidence demonstrated that the severity and prevalence of depression decreased after surgery[267]. A meta-analysis reported the overall rate of suicide after surgery was 0.3%, which was less than the general population rate of 1.4%[268]. Previous studies have documented a higher risk of suicide, especially in patients with underlying psychiatric disorders[269,270]. The possibility of higher risk of self-harm and suicide attempt after surgery was also suggested in another meta-analysis[271]. The International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) position statement considers severe and untreated psychiatric conditions like bipolar disorders, schizophrenia, active alcohol, and substance abuse, and bulimia nervosa contraindications for surgery[272]. Preoperative and postoperative psychosocial interventions, especially cognitive behavioral therapy, positively impacted eating behaviors such as binge eating and emotional eating and psychological functioning, including quality of life, depression, and anxiety[273]. The panel suggests psychological assessment to identify underlying comorbidities like depression and eating disorders and rule out alcohol and substance abuse and other frank psychiatric conditions that may interfere with surgical outcome. The patient’s perception about contributors to obesity should be discussed, and the ability to cope with lifestyle changes after surgery as well as self-harm tendency should be assessed. Psychosocial interventions such as cognitive behavioral therapy might be beneficial, but structured RCTs analyzing the effect of such a strategy are few.

**STRATEGIES FOR PREOPERATIVE WEIGHT LOSS**

***Recommendation 39***

The benefits of preoperative weight loss have not been consistently proven though it has been mandated as a prerequisite by many insurance companies. Lifestyle interventions resulting in weight loss should be encouraged, however evidence demonstrating its benefit is inconsistent (E).

***Recommendation 40***

More aggressive strategies like very low-calorie diet (VLCD) (450-800 kcal per day) and LCD (800-1200 kcal per day) for 2 wk or more, not only induce weight loss but additionally decrease liver volume and technically assist in performing laparoscopy. There is lack of evidence to routinely recommend weight loss with VLCD and LCD before surgery although it can be considered as per institutional practice (C).

***Discussion***

Preoperative lifestyle changes lead to a mean weight loss of 7.42 kg in a meta-analysis but there was no effect on mortality or morbidity. The hospital stay was however reduced in the weight-loss group[274]. A meta-analysis suggested that intra-gastric balloon placement and very low-calorie diet (450-800 kcal per day) were the two most effective ways of achieving preoperative weight loss, while another meta-analysis in patients with BMI ≥ 50 kg/m2 found only LSG and VLCD to be beneficial as bridging interventions[275,276]. Both LCD and VLCD induce weight loss and result in liver volume reduction[277,278]. The meta-analysis by Naseer *et al*[279] included four RCTs using VLCD and four other employing LCD. The authors inferred that the likelihood of achieving 5% weight loss was highest with a three week 700-1050 kcal diet, comprising of moderate carbohydrate, high protein and low or moderate fat. Though both LCD and VLCD cause preoperative weight loss the utility of such a strategy in improving perioperative outcome has not been validated[200]. The recommendation for preoperative weight loss to reduce liver size in order to improve the technical aspects of surgery was downgraded due to inconsistent evidence in the AACE/TOS/ASMBS/OMA/ASA guidelines published in 2019[33].

**CONCLUSION**

Obesity and DM are complex medical conditions and metabolic surgery is one of the few therapeutic options that alter their tendency for recidivism and progression. Individuals with diabetes are eligible for surgery at lower BMI cut-offs and emerging evidence suggests that the BMI threshold might be further decreased for Asians. Appropriate medical management of these disorders is however a critical prerequisite for surgery. Our statement provides suggestions for systematically addressing the various conditions associated with DM and obesity that requires optimization before surgery. Dissemination and implementation of these guidelines would help to standardize the management of these comorbidities and improve the perioperative and long-term outcomes. Though these guidelines are comprehensive and up to date, more effort would be needed constantly, to update the rapidly evolving medical literature pertaining to this subject.

**ACKNOWLEDGEMENTS**

The authors would like to thank Dr. David Cummings for his guidance and suggestions.

**REFERENCES**

1 **Kalra S**, Kapoor N, Bhattacharya S, Aydin H, Coetzee A. Barocrinology: The Endocrinology of Obesity from Bench to Bedside. *Med Sci (Basel)* 2020; **8** [PMID: 33371340 DOI: 10.3390/medsci8040051]

2 **Moore EC**, Pories WJ. Metabolic surgery is no longer just bariatric surgery. *Diabetes Technol Ther* 2014; **16** Suppl 1: S78-S84 [PMID: 24479602 DOI: 10.1089/dia.2014.1509]

3 **Buchwald H**, Buchwald JN. Metabolic (Bariatric and Nonbariatric) Surgery for Type 2 Diabetes: A Personal Perspective Review. *Diabetes Care* 2019; **42**: 331-340 [PMID: 30665965 DOI: 10.2337/dc17-2654]

4 **Grant RW**, Kirkman MS. Trends in the evidence level for the American Diabetes Association's "Standards of Medical Care in Diabetes" from 2005 to 2014. *Diabetes Care* 2015; **38**: 6-8 [PMID: 25538309 DOI: 10.2337/dc14-2142]

5 **Kalra S**, Kapoor N, Kota S, Das S. Person-centred Obesity Care - Techniques, Thresholds, Tools and Targets. *Eur Endocrinol* 2020; **16**: 11-13 [PMID: 32595763 DOI: 10.17925/EE.2020.16.1.11]

6 **Kapoor N**, Kalra S, Kota S, Das S, Jiwanmall S, Sahay R. The SECURE model: A comprehensive approach for obesity management. *J Pak Med Assoc* 2020; **70**: 1468-1469s [PMID: 32794511]

7 Obesity: preventing and managing the global epidemic. Report of a WHO consultation. *World Health Organ Tech Rep Ser* 2000; **894**: i-xii, 1-253 [PMID: 11234459]

8 **World Health Organization**. Obesity and overweight. [cited 10 February 2021]. Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight

9 **Hales CM**, Carroll MD, Fryar CD, Ogden CL. Prevalence of Obesity and Severe Obesity Among Adults: United States, 2017-2018. *NCHS Data Brief* 2020: 1-8 [PMID: 32487284]

10 **Al-Goblan AS**, Al-Alfi MA, Khan MZ. Mechanism linking diabetes mellitus and obesity. *Diabetes Metab Syndr Obes* 2014; **7**: 587-591 [PMID: 25506234 DOI: 10.2147/DMSO.S67400]

11 **Saeedi P**, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, Colagiuri S, Guariguata L, Motala AA, Ogurtsova K, Shaw JE, Bright D, Williams R; IDF Diabetes Atlas Committee. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. *Diabetes Res Clin Pract* 2019; **157**: 107843 [PMID: 31518657 DOI: 10.1016/j.diabres.2019.107843]

12 **Kalra S**. Diabesity. *J Pak Med Assoc* 2013; **63**: 532-534 [PMID: 23905459]

13 **Twig G**, Afek A, Derazne E, Tzur D, Cukierman-Yaffe T, Gerstein HC, Tirosh A. Diabetes risk among overweight and obese metabolically healthy young adults. *Diabetes Care* 2014; **37**: 2989-2995 [PMID: 25139886 DOI: 10.2337/dc14-0869]

14 **Vistisen D**, Witte DR, Tabák AG, Herder C, Brunner EJ, Kivimäki M, Færch K. Patterns of obesity development before the diagnosis of type 2 diabetes: the Whitehall II cohort study. *PLoS Med* 2014; **11**: e1001602 [PMID: 24523667 DOI: 10.1371/journal.pmed.1001602]

15 **Mozaffarian D**, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, de Ferranti S, Després JP, Fullerton HJ, Howard VJ, Huffman MD, Judd SE, Kissela BM, Lackland DT, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Matchar DB, McGuire DK, Mohler ER 3rd, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Willey JZ, Woo D, Yeh RW, Turner MB; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics--2015 update: a report from the American Heart Association. *Circulation* 2015; **131**: e29-322 [PMID: 25520374 DOI: 10.1161/CIR.0000000000000152]

16 **Deurenberg P**, Deurenberg-Yap M, Guricci S. Asians are different from Caucasians and from each other in their body mass index/body fat per cent relationship. *Obes Rev* 2002; **3**: 141-146 [PMID: 12164465 DOI: 10.1046/j.1467-789x.2002.00065.x]

17 **Kapoor N**, Lotfaliany M, Sathish T, Thankappan KR, Thomas N, Furler J, Oldenburg B, Tapp RJ. Prevalence of normal weight obesity and its associated cardio-metabolic risk factors - Results from the baseline data of the Kerala Diabetes Prevention Program (KDPP). *PLoS One* 2020; **15**: e0237974 [PMID: 32841271 DOI: 10.1371/journal.pone.0237974]

18 **Pacific WHORO for the W**. The Asia-Pacific Perspective : Redefining Obesity and Its Treatment. Sydney: Health Communications Australia. [cited 10 February 2021]. Available from: https://apps.who.int/iris/handle/10665/206936

19 **Kapoor N**, Furler J, Paul TV, Thomas N, Oldenburg B. Ethnicity-specific cut-offs that predict co-morbidities: the way forward for optimal utility of obesity indicators. *J Biosoc Sci* 2019; **51**: 624-626 [PMID: 30944046 DOI: 10.1017/S0021932019000178]

20 **American Diabetes Association**. 2. Classification and Diagnosis of Diabetes: *Standards of Medical Care in Diabetes-2020*. *Diabetes Care* 2020; **43**: S14-S31 [PMID: 31862745 DOI: 10.2337/dc20-S002]

21 **World Health Organization**. International Diabetes Federation. Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycaemia: Report of a WHO/IDF Consultation. 2006. [cited 10 February 2021]. Available from: http://www.who.int/diabetes/publications/diagnosis\_diabetes2006/en/

22 **Rubino F**, Nathan DM, Eckel RH, Schauer PR, Alberti KG, Zimmet PZ, Del Prato S, Ji L, Sadikot SM, Herman WH, Amiel SA, Kaplan LM, Taroncher-Oldenburg G, Cummings DE; Delegates of the 2nd Diabetes Surgery Summit. Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations. *Surg Obes Relat Dis* 2016; **12**: 1144-1162 [PMID: 27568469 DOI: 10.1016/j.soard.2016.05.018]

23 **Billeter AT**, Eichel S, Scheurlen KM, Probst P, Kopf S, Müller-Stich BP. Meta-analysis of metabolic surgery versus medical treatment for macrovascular complications and mortality in patients with type 2 diabetes. *Surg Obes Relat Dis* 2019; **15**: 1197-1210 [PMID: 31201113 DOI: 10.1016/j.soard.2019.04.029]

24 **Billeter AT**, Scheurlen KM, Probst P, Eichel S, Nickel F, Kopf S, Fischer L, Diener MK, Nawroth PP, Müller-Stich BP. Meta-analysis of metabolic surgery versus medical treatment for microvascular complications in patients with type 2 diabetes mellitus. *Br J Surg* 2018; **105**: 168-181 [PMID: 29405276 DOI: 10.1002/bjs.10724]

25 **Yan G**, Wang J, Zhang J, Gao K, Zhao Q, Xu X. Long-term outcomes of macrovascular diseases and metabolic indicators of bariatric surgery for severe obesity type 2 diabetes patients with a meta-analysis. *PLoS One* 2019; **14**: e0224828 [PMID: 31794559 DOI: 10.1371/journal.pone.0224828]

26 **Sjöström L**, Peltonen M, Jacobson P, Ahlin S, Andersson-Assarsson J, Anveden Å, Bouchard C, Carlsson B, Karason K, Lönroth H, Näslund I, Sjöström E, Taube M, Wedel H, Svensson PA, Sjöholm K, Carlsson LM. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. *JAMA* 2014; **311**: 2297-2304 [PMID: 24915261 DOI: 10.1001/jama.2014.5988]

27 **Cummings DE**, Cohen RV. Bariatric/Metabolic Surgery to Treat Type 2 Diabetes in Patients With a BMI < 35 kg/m2. *Diabetes Care* 2016; **39**: 924-933 [PMID: 27222550 DOI: 10.2337/dc16-0350]

28 **Li Q**, Chen L, Yang Z, Ye Z, Huang Y, He M, Zhang S, Feng X, Gong W, Zhang Z, Zhao W, Liu C, Qu S, Hu R. Metabolic effects of bariatric surgery in type 2 diabetic patients with body mass index < 35 kg/m2. *Diabetes Obes Metab* 2012; **14**: 262-270 [PMID: 22051116 DOI: 10.1111/j.1463-1326.2011.01524.x]

29 **Müller-Stich BP**, Senft JD, Warschkow R, Kenngott HG, Billeter AT, Vit G, Helfert S, Diener MK, Fischer L, Büchler MW, Nawroth PP. Surgical versus medical treatment of type 2 diabetes mellitus in nonseverely obese patients: a systematic review and meta-analysis. *Ann Surg* 2015; **261**: 421-429 [PMID: 25405560 DOI: 10.1097/SLA.0000000000001014]

30 **Ji G**, Li P, Li W, Sun X, Yu Z, Li R, Zhu L, Zhu S. The Effect of Bariatric Surgery on Asian Patients with Type 2 Diabetes Mellitus and Body Mass Index < 30 kg/m2: a Systematic Review and Meta-analysis. *Obes Surg* 2019; **29**: 2492-2502 [PMID: 30972637 DOI: 10.1007/s11695-019-03861-0]

31 **Rubio-Almanza M**, Hervás-Marín D, Cámara-Gómez R, Caudet-Esteban J, Merino-Torres JF. Does Metabolic Surgery Lead to Diabetes Remission in Patients with BMI < 30 kg/m2?: a Meta-analysis. *Obes Surg* 2019; **29**: 1105-1116 [PMID: 30604080 DOI: 10.1007/s11695-018-03654-x]

32 **Chen Y**, Zeng G, Tan J, Tang J, Ma J, Rao B. Impact of roux-en Y gastric bypass surgery on prognostic factors of type 2 diabetes mellitus: meta-analysis and systematic review. *Diabetes Metab Res Rev* 2015; **31**: 653-662 [PMID: 25387821 DOI: 10.1002/dmrr.2622]

33 **Mechanick JI**, Kushner RF, Sugerman HJ. Partial retraction. Retraction of specific recommendations regarding bariatric surgery for children and adolescents in "Executive summary of the recommendations of the American Association of Clinical Endocrinologists, the Obesity Society, and American Society for Metabolic & Bariatric Surgery medical guidelines for clinical practice for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient" (Endocr Pract. 2008;14[3]:318-336). *Endocr Pract* 2008; **14**: 650 [PMID: 18754175 DOI: 10.4158/GL-2019-0406]

34 **Butterworth J**, Deguara J, Borg CM. Bariatric Surgery, Polycystic Ovary Syndrome, and Infertility. *J Obes* 2016; **2016**: 1871594 [PMID: 27965894 DOI: 10.1155/2016/1871594]

35 **O'Brien PE**, Hindle A, Brennan L, Skinner S, Burton P, Smith A, Crosthwaite G, Brown W. Long-Term Outcomes After Bariatric Surgery: a Systematic Review and Meta-analysis of Weight Loss at 10 or More Years for All Bariatric Procedures and a Single-Centre Review of 20-Year Outcomes After Adjustable Gastric Banding. *Obes Surg* 2019; **29**: 3-14 [PMID: 30293134 DOI: 10.1007/s11695-018-3525-0]

36 **Han Y**, Jia Y, Wang H, Cao L, Zhao Y. Comparative analysis of weight loss and resolution of comorbidities between laparoscopic sleeve gastrectomy and Roux-en-Y gastric bypass: A systematic review and meta-analysis based on 18 studies. *Int J Surg* 2020; **76**: 101-110 [PMID: 32151750 DOI: 10.1016/j.ijsu.2020.02.035]

37 **Gu L**, Huang X, Li S, Mao D, Shen Z, Khadaroo PA, Ng DM, Chen P. A meta-analysis of the medium- and long-term effects of laparoscopic sleeve gastrectomy and laparoscopic Roux-en-Y gastric bypass. *BMC Surg* 2020; **20**: 30 [PMID: 32050953 DOI: 10.1186/s12893-020-00695-x]

38 **Madadi F**, Jawad R, Mousati I, Plaeke P, Hubens G. Remission of Type 2 Diabetes and Sleeve Gastrectomy in Morbid Obesity: a Comparative Systematic Review and Meta-analysis. *Obes Surg* 2019; **29**: 4066-4076 [PMID: 31655953 DOI: 10.1007/s11695-019-04199-3]

39 **Hayoz C**, Hermann T, Raptis DA, Brönnimann A, Peterli R, Zuber M. Comparison of metabolic outcomes in patients undergoing laparoscopic roux-en-Y gastric bypass versus sleeve gastrectomy - a systematic review and meta-analysis of randomised controlled trials. *Swiss Med Wkly* 2018; **148**: w14633 [PMID: 30035801 DOI: 10.4414/smw.2018.14633]

40 **Yu J**, Zhou X, Li L, Li S, Tan J, Li Y, Sun X. The long-term effects of bariatric surgery for type 2 diabetes: systematic review and meta-analysis of randomized and non-randomized evidence. *Obes Surg* 2015; **25**: 143-158 [PMID: 25355456 DOI: 10.1007/s11695-014-1460-2]

41 **Panunzi S**, De Gaetano A, Carnicelli A, Mingrone G. Predictors of remission of diabetes mellitus in severely obese individuals undergoing bariatric surgery: do BMI or procedure choice matter? A meta-analysis. *Ann Surg* 2015; **261**: 459-467 [PMID: 25361217 DOI: 10.1097/SLA.0000000000000863]

42 **Schauer PR**, Bhatt DL, Kirwan JP, Wolski K, Aminian A, Brethauer SA, Navaneethan SD, Singh RP, Pothier CE, Nissen SE, Kashyap SR; STAMPEDE Investigators. Bariatric Surgery versus Intensive Medical Therapy for Diabetes - 5-Year Outcomes. *N Engl J Med* 2017; **376**: 641-651 [PMID: 28199805 DOI: 10.1056/NEJMoa1600869]

43 **Chang SH**, Stoll CR, Song J, Varela JE, Eagon CJ, Colditz GA. The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003-2012. *JAMA Surg* 2014; **149**: 275-287 [PMID: 24352617 DOI: 10.1001/jamasurg.2013.3654]

44 **Buchwald H**, Estok R, Fahrbach K, Banel D, Jensen MD, Pories WJ, Bantle JP, Sledge I. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. *Am J Med* 2009; **122**: 248-256.e5 [PMID: 19272486 DOI: 10.1016/j.amjmed.2008.09.041]

45 **Buse JB**, Caprio S, Cefalu WT, Ceriello A, Del Prato S, Inzucchi SE, McLaughlin S, Phillips GL 2nd, Robertson RP, Rubino F, Kahn R, Kirkman MS. How do we define cure of diabetes? *Diabetes Care* 2009; **32**: 2133-2135 [PMID: 19875608 DOI: 10.2337/dc09-9036]

46 **Nagi D,** Hambling C, Taylor R. Remission of type 2 diabetes: a position statement from the Association of British Clinical Diabetologists (ABCD) and the Primary Care Diabetes Society (PCDS). *Br J Diabetes* 2019; **19**: 73-76 [DOI: 10.15277/bjd.2019.221]

47 **Kalra S**, Singal A, Lathia T. What's in a Name? Redefining Type 2 Diabetes Remission. *Diabetes Ther* 2021; **12**: 647-654 [PMID: 33491112 DOI: 10.1007/s13300-020-00990-z]

48 **Hirst JA**, Farmer AJ, Ali R, Roberts NW, Stevens RJ. Quantifying the effect of metformin treatment and dose on glycemic control. *Diabetes Care* 2012; **35**: 446-454 [PMID: 22275444 DOI: 10.2337/dc11-1465]

49 **Park JY**. Prediction of Type 2 Diabetes Remission after Bariatric or Metabolic Surgery. *J Obes Metab Syndr* 2018; **27**: 213-222 [PMID: 31089566 DOI: 10.7570/jomes.2018.27.4.213]

50 **Panunzi S**, Carlsson L, De Gaetano A, Peltonen M, Rice T, Sjöström L, Mingrone G, Dixon JB. Determinants of Diabetes Remission and Glycemic Control After Bariatric Surgery. *Diabetes Care* 2016; **39**: 166-174 [PMID: 26628418 DOI: 10.2337/dc15-0575]

51 **Jindal R**, Gupta M, Ahuja A, Nain PS, Sharma P, Aggarwal A. Factors Determining Diabetic Remission after Sleeve Gastrectomy: A Prospective Study. *Niger J Surg* 2020; **26**: 66-71 [PMID: 32165840 DOI: 10.4103/njs.NJS\_9\_19]

52 **Huang X**, Liu T, Zhong M, Cheng Y, Hu S, Liu S. Predictors of glycemic control after sleeve gastrectomy versus Roux-en-Y gastric bypass: A meta-analysis, meta-regression, and systematic review. *Surg Obes Relat Dis* 2018; **14**: 1822-1831 [PMID: 30385071 DOI: 10.1016/j.soard.2018.08.027]

53 **Stenberg E**, Olbers T, Cao Y, Sundbom M, Jans A, Ottosson J, Naslund E, Näslund I. Factors determining chance of type 2 diabetes remission after Roux-en-Y gastric bypass surgery: a nationwide cohort study in 8057 Swedish patients. *BMJ Open Diabetes Res Care* 2021; **9** [PMID: 33990366 DOI: 10.1136/bmjdrc-2020-002033]

54 **Jans A**, Näslund I, Ottosson J, Szabo E, Näslund E, Stenberg E. Duration of type 2 diabetes and remission rates after bariatric surgery in Sweden 2007-2015: A registry-based cohort study. *PLoS Med* 2019; **16**: e1002985 [PMID: 31747392 DOI: 10.1371/journal.pmed.1002985]

55 **Nudotor RD**, Prokopowicz G, Abbey EJ, Gonzalez A, Canner JK, Steele KE. Comparative Effectiveness of Roux-en Y Gastric Bypass Versus Vertical Sleeve Gastrectomy for Sustained Remission of Type 2 Diabetes Mellitus. *J Surg Res* 2021; **261**: 407-416 [PMID: 33515868 DOI: 10.1016/j.jss.2020.12.024]

56 **Vangoitsenhoven R**, Wilson RL, Cherla DV, Tu C, Kashyap SR, Cummings DE, Schauer PR, Aminian A. Presence of Liver Steatosis Is Associated With Greater Diabetes Remission After Gastric Bypass Surgery. *Diabetes Care* 2021; **44**: 321-325 [PMID: 33323476 DOI: 10.2337/dc20-0150]

57 **Yu H**, Di J, Bao Y, Zhang P, Zhang L, Tu Y, Han X, Jia W. Visceral fat area as a new predictor of short-term diabetes remission after Roux-en-Y gastric bypass surgery in Chinese patients with a body mass index less than 35 kg/m2. *Surg Obes Relat Dis* 2015; **11**: 6-11 [PMID: 25547054 DOI: 10.1016/j.soard.2014.06.019]

58 **Carbone F**, Adami G, Liberale L, Bonaventura A, Bertolotto M, Andraghetti G, Scopinaro N, Camerini GB, Papadia FS, Cordera R, Dallegri F, Montecucco F. Serum levels of osteopontin predict diabetes remission after bariatric surgery. *Diabetes Metab* 2019; **45**: 356-362 [PMID: 30268840 DOI: 10.1016/j.diabet.2018.09.007]

59 **Lee WJ**, Chong K, Chen JC, Ser KH, Lee YC, Tsou JJ, Chen SC. Predictors of diabetes remission after bariatric surgery in Asia. *Asian J Surg* 2012; **35**: 67-73 [PMID: 22720861 DOI: 10.1016/j.asjsur.2012.04.010]

60 **Bonaventura A**, Liberale L, Carbone F, Scopinaro N, Camerini G, Papadia FS, Cordera R, Dallegri F, Adami GF, Montecucco F. High baseline C-reactive protein levels predict partial type 2 diabetes mellitus remission after biliopancreatic diversion. *Nutr Metab Cardiovasc Dis* 2017; **27**: 423-429 [PMID: 28284664 DOI: 10.1016/j.numecd.2017.01.007]

61 **Wang GF**, Yan YX, Xu N, Yin D, Hui Y, Zhang JP, Han GJ, Ma N, Wu Y, Xu JZ, Yang T. Predictive factors of type 2 diabetes mellitus remission following bariatric surgery: a meta-analysis. *Obes Surg* 2015; **25**: 199-208 [PMID: 25103403 DOI: 10.1007/s11695-014-1391-y]

62 **Dang JT**, Sheppard C, Kim D, Switzer N, Shi X, Tian C, de Gara C, Karmali S, Birch DW. Predictive factors for diabetes remission after bariatric surgery. *Can J Surg* 2019; **62**: 315-319 [PMID: 31550092 DOI: 10.1503/cjs.014516]

63 **Lee MH**, Lee WJ, Chong K, Chen JC, Ser KH, Lee YC, Chen SC. Predictors of long-term diabetes remission after metabolic surgery. *J Gastrointest Surg* 2015; **19**: 1015-1021 [PMID: 25840670 DOI: 10.1007/s11605-015-2808-1]

64 **Bonaventura A**, Liberale L, Carbone F, Vecchié A, Bonomi A, Scopinaro N, Camerini GB, Papadia FS, Maggi D, Cordera R, Dallegri F, Adami G, Montecucco F. Baseline neutrophil-to-lymphocyte ratio is associated with long-term T2D remission after metabolic surgery. *Acta Diabetol* 2019; **56**: 741-748 [PMID: 30993529 DOI: 10.1007/s00592-019-01345-2]

65 **Hardy OT**, Czech MP, Corvera S. What causes the insulin resistance underlying obesity? *Curr Opin Endocrinol Diabetes Obes* 2012; **19**: 81-87 [PMID: 22327367 DOI: 10.1097/MED.0b013e3283514e13]

66 **Patel P**, Abate N. Body fat distribution and insulin resistance. *Nutrients* 2013; **5**: 2019-2027 [PMID: 23739143 DOI: 10.3390/nu5062019]

67 **Ji B**, Qu H, Wang H, Wei H, Deng H. Association Between the Visceral Adiposity Index and Homeostatic Model Assessment of Insulin Resistance in Participants With Normal Waist Circumference. *Angiology* 2017; **68**: 716-721 [PMID: 28743220 DOI: 10.1177/0003319716682120]

68 **Park YW**, Allison DB, Heymsfield SB, Gallagher D. Larger amounts of visceral adipose tissue in Asian Americans. *Obes Res* 2001; **9**: 381-387 [PMID: 11445659 DOI: 10.1038/oby.2001.49]

69 **Williams R**, Periasamy M. Genetic and Environmental Factors Contributing to Visceral Adiposity in Asian Populations. *Endocrinol Metab (Seoul)* 2020; **35**: 681-695 [PMID: 33397033 DOI: 10.3803/EnM.2020.772]

70 **Amato MC**, Giordano C, Galia M, Criscimanna A, Vitabile S, Midiri M, Galluzzo A; AlkaMeSy Study Group. Visceral Adiposity Index: a reliable indicator of visceral fat function associated with cardiometabolic risk. *Diabetes Care* 2010; **33**: 920-922 [PMID: 20067971 DOI: 10.2337/dc09-1825]

71 **Ke Z**, Li F, Gao Y, Tan D, Sun F, Zhou X, Chen J, Lin X, Zhu Z, Tong W. The Use of Visceral Adiposity Index to Predict Diabetes Remission in Low BMI Chinese Patients After Bariatric Surgery. *Obes Surg* 2021; **31**: 805-812 [PMID: 33063158 DOI: 10.1007/s11695-020-05034-w]

72 **Lee WJ**, Hur KY, Lakadawala M, Kasama K, Wong SK, Chen SC, Lee YC, Ser KH. Predicting success of metabolic surgery: age, body mass index, C-peptide, and duration score. *Surg Obes Relat Dis* 2013; **9**: 379-384 [PMID: 22963817 DOI: 10.1016/j.soard.2012.07.015]

73 **Still CD**, Wood GC, Benotti P, Petrick AT, Gabrielsen J, Strodel WE, Ibele A, Seiler J, Irving BA, Celaya MP, Blackstone R, Gerhard GS, Argyropoulos G. Preoperative prediction of type 2 diabetes remission after Roux-en-Y gastric bypass surgery: a retrospective cohort study. *Lancet Diabetes Endocrinol* 2014; **2**: 38-45 [PMID: 24579062 DOI: 10.1016/S2213-8587(13)70070-6]

74 **Aminian A**, Brethauer SA, Andalib A, Nowacki AS, Jimenez A, Corcelles R, Hanipah ZN, Punchai S, Bhatt DL, Kashyap SR, Burguera B, Lacy AM, Vidal J, Schauer PR. Individualized Metabolic Surgery Score: Procedure Selection Based on Diabetes Severity. *Ann Surg* 2017; **266**: 650-657 [PMID: 28742680 DOI: 10.1097/SLA.0000000000002407]

75 **Chen JC**, Hsu NY, Lee WJ, Chen SC, Ser KH, Lee YC. Prediction of type 2 diabetes remission after metabolic surgery: a comparison of the individualized metabolic surgery score and the ABCD score. *Surg Obes Relat Dis* 2018; **14**: 640-645 [PMID: 29526672 DOI: 10.1016/j.soard.2018.01.027]

76 **Lee WJ**, Chong K, Chen SC, Zachariah J, Ser KH, Lee YC, Chen JC. Preoperative Prediction of Type 2 Diabetes Remission After Gastric Bypass Surgery: a Comparison of DiaRem Scores and ABCD Scores. *Obes Surg* 2016; **26**: 2418-2424 [PMID: 26932813 DOI: 10.1007/s11695-016-2120-5]

77 **Luo Y**, Guo Z, He H, Yang Y, Zhao S, Mo Z. Predictive Model of Type 2 Diabetes Remission after Metabolic Surgery in Chinese Patients. *Int J Endocrinol* 2020; **2020**: 2965175 [PMID: 33488705 DOI: 10.1155/2020/2965175]

78 **Abdelmalak BB**, Knittel J, Abdelmalak JB, Dalton JE, Christiansen E, Foss J, Argalious M, Zimmerman R, Van den Berghe G. Preoperative blood glucose concentrations and postoperative outcomes after elective non-cardiac surgery: an observational study. *Br J Anaesth* 2014; **112**: 79-88 [PMID: 24009267 DOI: 10.1093/bja/aet297]

79 **Han HS**, Kang SB. Relations between long-term glycemic control and postoperative wound and infectious complications after total knee arthroplasty in type 2 diabetics. *Clin Orthop Surg* 2013; **5**: 118-123 [PMID: 23730475 DOI: 10.4055/cios.2013.5.2.118]

80 **Garg R**, Schuman B, Bader A, Hurwitz S, Turchin A, Underwood P, Metzger C, Rein R, Lortie M. Effect of Preoperative Diabetes Management on Glycemic Control and Clinical Outcomes After Elective Surgery. *Ann Surg* 2018; **267**: 858-862 [PMID: 28549013 DOI: 10.1097/SLA.0000000000002323]

81 **Duggan EW**, Carlson K, Umpierrez GE. Perioperative Hyperglycemia Management: An Update. *Anesthesiology* 2017; **126**: 547-560 [PMID: 28121636 DOI: 10.1097/ALN.0000000000001515]

82 **Houlden RL**, Yen JL, Moore S. Effectiveness of an Interprofessional Glycemic Optimization Clinic on Preoperative Glycated Hemoglobin Levels for Adult Patients With Type 2 Diabetes Undergoing Bariatric Surgery. *Can J Diabetes* 2018; **42**: 514-519 [PMID: 29530392 DOI: 10.1016/j.jcjd.2017.12.011]

83 **Perna M**, Romagnuolo J, Morgan K, Byrne TK, Baker M. Preoperative hemoglobin A1c and postoperative glucose control in outcomes after gastric bypass for obesity. *Surg Obes Relat Dis* 2012; **8**: 685-690 [PMID: 21982941 DOI: 10.1016/j.soard.2011.08.002]

84 **Chuah LL**, Miras AD, Papamargaritis D, Jackson SN, Olbers T, le Roux CW. Impact of perioperative management of glycemia in severely obese diabetic patients undergoing gastric bypass surgery. *Surg Obes Relat Dis* 2015; **11**: 578-584 [PMID: 25863535 DOI: 10.1016/j.soard.2014.11.004]

85 **Thompson RE**, Broussard EK, Flum DR, Wisse BE. Perioperative Glycemic Control During Colorectal Surgery. *Curr Diab Rep* 2016; **16**: 32 [PMID: 26923148 DOI: 10.1007/s11892-016-0722-x]

86 **Dhatariya K**, Levy N, Kilvert A, Watson B, Cousins D, Flanagan D, Hilton L, Jairam C, Leyden K, Lipp A, Lobo D, Sinclair-Hammersley M, Rayman G; Joint British Diabetes Societies. NHS Diabetes guideline for the perioperative management of the adult patient with diabetes. *Diabet Med* 2012; **29**: 420-433 [PMID: 22288687 DOI: 10.1111/j.1464-5491.2012.03582.x]

87 **Ochner CN**, Dambkowski CL, Yeomans BL, Teixeira J, Xavier Pi-Sunyer F. Pre-bariatric surgery weight loss requirements and the effect of preoperative weight loss on postoperative outcome. *Int J Obes (Lond)* 2012; **36**: 1380-1387 [PMID: 22508337 DOI: 10.1038/ijo.2012.60]

88 **Baldry EL**, Leeder PC, Idris IR. Pre-operative dietary restriction for patients undergoing bariatric surgery in the UK: observational study of current practice and dietary effects. *Obes Surg* 2014; **24**: 416-421 [PMID: 24214282 DOI: 10.1007/s11695-013-1125-6]

89 **de Boer IH**, Bangalore S, Benetos A, Davis AM, Michos ED, Muntner P, Rossing P, Zoungas S, Bakris G. Diabetes and Hypertension: A Position Statement by the American Diabetes Association. *Diabetes Care* 2017; **40**: 1273-1284 [PMID: 28830958 DOI: 10.2337/dci17-0026]

90 **Bangalore S**, Fakheri R, Toklu B, Messerli FH. Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials. *BMJ* 2016; **352**: i438 [PMID: 26868137 DOI: 10.1136/bmj.i438]

91 **Emdin CA**, Rahimi K, Neal B, Callender T, Perkovic V, Patel A. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. *JAMA* 2015; **313**: 603-615 [PMID: 25668264 DOI: 10.1001/jama.2014.18574]

92 **Fleisher LA**, Fleischmann KE, Auerbach AD, Barnason SA, Beckman JA, Bozkurt B, Davila-Roman VG, Gerhard-Herman MD, Holly TA, Kane GC, Marine JE, Nelson MT, Spencer CC, Thompson A, Ting HH, Uretsky BF, Wijeysundera DN; American College of Cardiology; American Heart Association. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. *J Am Coll Cardiol* 2014; **64**: e77-137 [PMID: 25091544 DOI: 10.1016/j.jacc.2014.07.944]

93 **American Diabetes Association.**. 10. Cardiovascular Disease and Risk Management: *Standards of Medical Care in Diabetes-2020*. *Diabetes Care* 2020; **43**: S111-S134 [PMID: 31862753 DOI: 10.2337/dc20-S010]

94 **van Klei WA**, Bryson GL, Yang H, Kalkman CJ, Wells GA, Beattie WS. The value of routine preoperative electrocardiography in predicting myocardial infarction after noncardiac surgery. *Ann Surg* 2007; **246**: 165-170 [PMID: 17667491 DOI: 10.1097/01.sla.0000261737.62514.63]

95 **Lee TH**, Marcantonio ER, Mangione CM, Thomas EJ, Polanczyk CA, Cook EF, Sugarbaker DJ, Donaldson MC, Poss R, Ho KK, Ludwig LE, Pedan A, Goldman L. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. *Circulation* 1999; **100**: 1043-1049 [PMID: 10477528 DOI: 10.1161/01.cir.100.10.1043]

96 **Gupta PK**, Gupta H, Sundaram A, Kaushik M, Fang X, Miller WJ, Esterbrooks DJ, Hunter CB, Pipinos II, Johanning JM, Lynch TG, Forse RA, Mohiuddin SM, Mooss AN. Development and validation of a risk calculator for prediction of cardiac risk after surgery. *Circulation* 2011; **124**: 381-387 [PMID: 21730309 DOI: 10.1161/CIRCULATIONAHA.110.015701]

97 **Dakik HA**, Chehab O, Eldirani M, Sbeity E, Karam C, Abou Hassan O, Msheik M, Hassan H, Msheik A, Kaspar C, Makki M, Tamim H. A New Index for Pre-Operative Cardiovascular Evaluation. *J Am Coll Cardiol* 2019; **73**: 3067-3078 [PMID: 31221255 DOI: 10.1016/j.jacc.2019.04.023]

98 **Bilimoria KY**, Liu Y, Paruch JL, Zhou L, Kmiecik TE, Ko CY, Cohen ME. Development and evaluation of the universal ACS NSQIP surgical risk calculator: a decision aid and informed consent tool for patients and surgeons. *J Am Coll Surg* 2013; **217**: 833-42.e1-3 [PMID: 24055383 DOI: 10.1016/j.jamcollsurg.2013.07.385]

99 **Fronczek J**, Polok K, Devereaux PJ, Górka J, Archbold RA, Biccard B, Duceppe E, Le Manach Y, Sessler DI, Duchińska M, Szczeklik W. External validation of the Revised Cardiac Risk Index and National Surgical Quality Improvement Program Myocardial Infarction and Cardiac Arrest calculator in noncardiac vascular surgery. *Br J Anaesth* 2019; **123**: 421-429 [PMID: 31256916 DOI: 10.1016/j.bja.2019.05.029]

100 **Gugliotti D**, Grant P, Jaber W, Aboussouan L, Bae C, Sessler D, Scahuer P, Kaw R. Challenges in cardiac risk assessment in bariatric surgery patients. *Obes Surg* 2008; **18**: 129-133 [PMID: 18066696 DOI: 10.1007/s11695-007-9281-1]

101 **DeMaria EJ**, Portenier D, Wolfe L. Obesity surgery mortality risk score: proposal for a clinically useful score to predict mortality risk in patients undergoing gastric bypass. *Surg Obes Relat Dis* 2007; **3**: 134-140 [PMID: 17386394 DOI: 10.1016/j.soard.2007.01.005]

102 **Thomas H**, Agrawal S. Systematic review of obesity surgery mortality risk score--preoperative risk stratification in bariatric surgery. *Obes Surg* 2012; **22**: 1135-1140 [PMID: 22535443 DOI: 10.1007/s11695-012-0663-7]

103 **Turner PL**, Saager L, Dalton J, Abd-Elsayed A, Roberman D, Melara P, Kurz A, Turan A. A nomogram for predicting surgical complications in bariatric surgery patients. *Obes Surg* 2011; **21**: 655-662 [PMID: 21161606 DOI: 10.1007/s11695-010-0325-6]

104 **Blackstone RP**, Cortés MC. Metabolic acuity score: effect on major complications after bariatric surgery. *Surg Obes Relat Dis* 2010; **6**: 267-273 [PMID: 20005783 DOI: 10.1016/j.soard.2009.09.010]

105 **Longitudinal Assessment of Bariatric Surgery (LABS) Consortium**, Flum DR, Belle SH, King WC, Wahed AS, Berk P, Chapman W, Pories W, Courcoulas A, McCloskey C, Mitchell J, Patterson E, Pomp A, Staten MA, Yanovski SZ, Thirlby R, Wolfe B. Perioperative safety in the longitudinal assessment of bariatric surgery. *N Engl J Med* 2009; **361**: 445-454 [PMID: 19641201 DOI: 10.1056/NEJMoa0901836]

106 **Haskins IN**, Amdur R, Vaziri K. The effect of smoking on bariatric surgical outcomes. *Surg Endosc* 2014; **28**: 3074-3080 [PMID: 24902816 DOI: 10.1007/s00464-014-3581-z]

107 **Chow A**, Neville A, Kolozsvari N. Smoking in bariatric surgery: a systematic review. *Surg Endosc* 2021; **35**: 3047-3066 [PMID: 32524412 DOI: 10.1007/s00464-020-07669-3]

108 **Devlin CA**, Smeltzer SC. Temporary Perioperative Tobacco Cessation: A Literature Review. *AORN J* 2017; **106**: 415-423.e5 [PMID: 29107259 DOI: 10.1016/j.aorn.2017.09.001]

109 **Veldheer S**, Yingst J, Rogers AM, Foulds J. Completion rates in a preoperative surgical weight loss program by tobacco use status. *Surg Obes Relat Dis* 2017; **13**: 842-847 [PMID: 28392255 DOI: 10.1016/j.soard.2017.02.004]

110 **van Huisstede A**, Biter LU, Luitwieler R, Castro Cabezas M, Mannaerts G, Birnie E, Taube C, Hiemstra PS, Braunstahl GJ. Pulmonary function testing and complications of laparoscopic bariatric surgery. *Obes Surg* 2013; **23**: 1596-1603 [PMID: 23515977 DOI: 10.1007/s11695-013-0928-9]

111 **Clavellina-Gaytán D**, Velázquez-Fernández D, Del-Villar E, Domínguez-Cherit G, Sánchez H, Mosti M, Herrera MF. Evaluation of spirometric testing as a routine preoperative assessment in patients undergoing bariatric surgery. *Obes Surg* 2015; **25**: 530-536 [PMID: 25240391 DOI: 10.1007/s11695-014-1420-x]

112 **Farina A**, Crimi E, Accogli S, Camerini G, Adami GF. Preoperative assessment of respiratory function in severely obese patients undergoing biliopancreatic diversion. *Eur Surg Res* 2012; **48**: 106-110 [PMID: 22538503 DOI: 10.1159/000337744]

113 **Loo GH**, Rajan R, Mohd Tamil A, Ritza Kosai N. Prevalence of obstructive sleep apnea in an Asian bariatric population: an underdiagnosed dilemma. *Surg Obes Relat Dis* 2020; **16**: 778-783 [PMID: 32199766 DOI: 10.1016/j.soard.2020.02.003]

114 **Sareli AE**, Cantor CR, Williams NN, Korus G, Raper SE, Pien G, Hurley S, Maislin G, Schwab RJ. Obstructive sleep apnea in patients undergoing bariatric surgery--a tertiary center experience. *Obes Surg* 2011; **21**: 316-327 [PMID: 19669842 DOI: 10.1007/s11695-009-9928-1]

115 **Yeh PS**, Lee YC, Lee WJ, Chen SB, Ho SJ, Peng WB, Tsao CC, Chiu HL. Clinical predictors of obstructive sleep apnea in Asian bariatric patients. *Obes Surg* 2010; **20**: 30-35 [PMID: 19434465 DOI: 10.1007/s11695-009-9854-2]

116 **Reed K**, Pengo MF, Steier J. Screening for sleep-disordered breathing in a bariatric population. *J Thorac Dis* 2016; **8**: 268-275 [PMID: 26904267 DOI: 10.3978/j.issn.2072-1439.2015.11.58]

117 **Iglesias AÚ**, Romero LA, Rodríguez AE. Perioperative Risks of Untreated Obstructive Sleep Apnea in the Bariatric Surgery Patient: a Retrospective Study. *Obes Surg* 2016; **26**: 2779-2780 [PMID: 27605375 DOI: 10.1007/s11695-016-2335-5]

118 **Kong WT**, Chopra S, Kopf M, Morales C, Khan S, Zuccala K, Choi L, Chronakos J. Perioperative Risks of Untreated Obstructive Sleep Apnea in the Bariatric Surgery Patient: a Retrospective Study. *Obes Surg* 2016; **26**: 2886-2890 [PMID: 27206775 DOI: 10.1007/s11695-016-2203-3]

119 **de Raaff CAL**, Gorter-Stam MAW, de Vries N, Sinha AC, Jaap Bonjer H, Chung F, Coblijn UK, Dahan A, van den Helder RS, Hilgevoord AAJ, Hillman DR, Margarson MP, Mattar SG, Mulier JP, Ravesloot MJL, Reiber BMM, van Rijswijk AS, Singh PM, Steenhuis R, Tenhagen M, Vanderveken OM, Verbraecken J, White DP, van der Wielen N, van Wagensveld BA. Perioperative management of obstructive sleep apnea in bariatric surgery: a consensus guideline. *Surg Obes Relat Dis* 2017; **13**: 1095-1109 [PMID: 28666588 DOI: 10.1016/j.soard.2017.03.022]

120 **Amra B**, Rahmati B, Soltaninejad F, Feizi A. Screening Questionnaires for Obstructive Sleep Apnea: An Updated Systematic Review. *Oman Med J* 2018; **33**: 184-192 [PMID: 29896325 DOI: 10.5001/omj.2018.36]

121 **Chesson AL Jr**, Berry RB, Pack A; American Academy of Sleep Medicine; American Thoracic Society; American College of Chest Physicians. Practice parameters for the use of portable monitoring devices in the investigation of suspected obstructive sleep apnea in adults. *Sleep* 2003; **26**: 907-913 [PMID: 14655928 DOI: 10.1093/sleep/26.7.907]

122 **ASMBS Clinical Issues Committee**. Peri-operative management of obstructive sleep apnea. *Surg Obes Relat Dis* 2012; **8**: e27-e32 [PMID: 22503595 DOI: 10.1016/j.soard.2012.03.003]

123 **Mokhlesi B**, Tulaimat A, Faibussowitsch I, Wang Y, Evans AT. Obesity hypoventilation syndrome: prevalence and predictors in patients with obstructive sleep apnea. *Sleep Breath* 2007; **11**: 117-124 [PMID: 17187265 DOI: 10.1007/s11325-006-0092-8]

124 **Tran K**, Wang L, Gharaibeh S, Kempke N, Rao Kashyap S, Cetin D, Aboussouan LS, Mehra R. Elucidating Predictors of Obesity Hypoventilation Syndrome in a Large Bariatric Surgery Cohort. *Ann Am Thorac Soc* 2020; **17**: 1279-1288 [PMID: 32526148 DOI: 10.1513/AnnalsATS.202002-135OC]

125 **Masa JF**, Pépin JL, Borel JC, Mokhlesi B, Murphy PB, Sánchez-Quiroga MÁ. Obesity hypoventilation syndrome. *Eur Respir Rev* 2019; **28** [PMID: 30872398 DOI: 10.1183/16000617.0097-2018]

126 **Chau EH**, Lam D, Wong J, Mokhlesi B, Chung F. Obesity hypoventilation syndrome: a review of epidemiology, pathophysiology, and perioperative considerations. *Anesthesiology* 2012; **117**: 188-205 [PMID: 22614131 DOI: 10.1097/ALN.0b013e31825add60]

127 **Tseng EK**, Kolesar E, Handa P, Douketis JD, Anvari M, Tiboni M, Crowther MA, Siegal DM. Weight-adjusted tinzaparin for the prevention of venous thromboembolism after bariatric surgery. *J Thromb Haemost* 2018; **16**: 2008-2015 [PMID: 30099852 DOI: 10.1111/jth.14263]

128 **Ikesaka R**, Delluc A, Le Gal G, Carrier M. Efficacy and safety of weight-adjusted heparin prophylaxis for the prevention of acute venous thromboembolism among obese patients undergoing bariatric surgery: a systematic review and meta-analysis. *Thromb Res* 2014; **133**: 682-687 [PMID: 24508449 DOI: 10.1016/j.thromres.2014.01.021]

129 **Becattini C**, Agnelli G, Manina G, Noya G, Rondelli F. Venous thromboembolism after laparoscopic bariatric surgery for morbid obesity: clinical burden and prevention. *Surg Obes Relat Dis* 2012; **8**: 108-115 [PMID: 22014482 DOI: 10.1016/j.soard.2011.09.005]

130 **Finks JF**, English WJ, Carlin AM, Krause KR, Share DA, Banerjee M, Birkmeyer JD, Birkmeyer NJ; Michigan Bariatric Surgery Collaborative; Center for Healthcare Outcomes and Policy. Predicting risk for venous thromboembolism with bariatric surgery: results from the Michigan Bariatric Surgery Collaborative. *Ann Surg* 2012; **255**: 1100-1104 [PMID: 22566018 DOI: 10.1097/SLA.0b013e31825659d4]

131 **Dang JT**, Switzer N, Delisle M, Laffin M, Gill R, Birch DW, Karmali S. Predicting venous thromboembolism following laparoscopic bariatric surgery: development of the BariClot tool using the MBSAQIP database. *Surg Endosc* 2019; **33**: 821-831 [PMID: 30003351 DOI: 10.1007/s00464-018-6348-0]

132 **Nimeri AA**, Bautista J, Ibrahim M, Philip R, Al Shaban T, Maasher A, Altinoz A. Mandatory Risk Assessment Reduces Venous Thromboembolism in Bariatric Surgery Patients. *Obes Surg* 2018; **28**: 541-547 [PMID: 28836135 DOI: 10.1007/s11695-017-2909-x]

133 **Gambhir S**, Inaba CS, Alizadeh RF, Nahmias J, Hinojosa M, Smith BR, Nguyen NT, Daly S. Venous thromboembolism risk for the contemporary bariatric surgeon. *Surg Endosc* 2020; **34**: 3521-3526 [PMID: 31559578 DOI: 10.1007/s00464-019-07134-w]

134 **American Society for Metabolic and Bariatric Surgery Clinical Issues Committee**. ASMBS updated position statement on prophylactic measures to reduce the risk of venous thromboembolism in bariatric surgery patients. *Surg Obes Relat Dis* 2013; **9**: 493-497 [PMID: 23769113 DOI: 10.1016/j.soard.2013.03.006]

135 **Bartlett MA**, Mauck KF, Daniels PR. Prevention of venous thromboembolism in patients undergoing bariatric surgery. *Vasc Health Risk Manag* 2015; **11**: 461-477 [PMID: 26316771 DOI: 10.2147/VHRM.S73799]

136 **Di Lorenzo N**, Antoniou SA, Batterham RL, Busetto L, Godoroja D, Iossa A, Carrano FM, Agresta F, Alarçon I, Azran C, Bouvy N, Balaguè Ponz C, Buza M, Copaescu C, De Luca M, Dicker D, Di Vincenzo A, Felsenreich DM, Francis NK, Fried M, Gonzalo Prats B, Goitein D, Halford JCG, Herlesova J, Kalogridaki M, Ket H, Morales-Conde S, Piatto G, Prager G, Pruijssers S, Pucci A, Rayman S, Romano E, Sanchez-Cordero S, Vilallonga R, Silecchia G. Clinical practice guidelines of the European Association for Endoscopic Surgery (EAES) on bariatric surgery: update 2020 endorsed by IFSO-EC, EASO and ESPCOP. *Surg Endosc* 2020; **34**: 2332-2358 [PMID: 32328827 DOI: 10.1007/s00464-020-07555-y]

137 **Parikh M**, Liu J, Vieira D, Tzimas D, Horwitz D, Antony A, Saunders JK, Ude-Welcome A, Goodman A. Preoperative Endoscopy Prior to Bariatric Surgery: a Systematic Review and Meta-Analysis of the Literature. *Obes Surg* 2016; **26**: 2961-2966 [PMID: 27198238 DOI: 10.1007/s11695-016-2232-y]

138 **Bennett S**, Gostimir M, Shorr R, Mallick R, Mamazza J, Neville A. The role of routine preoperative upper endoscopy in bariatric surgery: a systematic review and meta-analysis. *Surg Obes Relat Dis* 2016; **12**: 1116-1125 [PMID: 27320221 DOI: 10.1016/j.soard.2016.04.012]

139 **García-Gómez-Heras S**, Garcia A, Zubiaga L, Artuñedo P, Ferrigni C, Duran M, Ruiz-Tovar J. Prevalence of Endoscopic Findings Before Bariatric Surgery and Their Influence on the Selection of the Surgical Technique. *Obes Surg* 2020; **30**: 4375-4380 [PMID: 32588172 DOI: 10.1007/s11695-020-04800-0]

140 **Şen O**, Türkçapar AG, Yerdel MA. Screening Esophagogastroduodenoscopy Before Laparoscopic Sleeve Gastrectomy: Results in 819 Patients. *J Laparoendosc Adv Surg Tech A* 2021; **31**: 672-675 [PMID: 32882153 DOI: 10.1089/lap.2020.0541]

141 **DuPree CE**, Blair K, Steele SR, Martin MJ. Laparoscopic sleeve gastrectomy in patients with preexisting gastroesophageal reflux disease : a national analysis. *JAMA Surg* 2014; **149**: 328-334 [PMID: 24500799 DOI: 10.1001/jamasurg.2013.4323]

142 **Yeung KTD**, Penney N, Ashrafian L, Darzi A, Ashrafian H. Does Sleeve Gastrectomy Expose the Distal Esophagus to Severe Reflux?: A Systematic Review and Meta-analysis. *Ann Surg* 2020; **271**: 257-265 [PMID: 30921053 DOI: 10.1097/SLA.0000000000003275]

143 **Carabotti M**, Avallone M, Cereatti F, Paganini A, Greco F, Scirocco A, Severi C, Silecchia G. Usefulness of Upper Gastrointestinal Symptoms as a Driver to Prescribe Gastroscopy in Obese Patients Candidate to Bariatric Surgery. A Prospective Study. *Obes Surg* 2016; **26**: 1075-1080 [PMID: 26328530 DOI: 10.1007/s11695-015-1861-x]

144 **Lorentzen J**, Medhus AW, Hertel JK, Borgeraas H, Karlsen TI, Kolotkin RL, Sandbu R, Sifrim D, Svanevik M, Hofsø D, Seip B, Hjelmesæth J. Erosive Esophagitis and Symptoms of Gastroesophageal Reflux Disease in Patients with Morbid Obesity with and without Type 2 Diabetes: a Cross-sectional Study. *Obes Surg* 2020; **30**: 2667-2675 [PMID: 32193740 DOI: 10.1007/s11695-020-04545-w]

145 **Wang S**, Wang Q, Xu L, Yu P, Li Q, Li X, Guo M, Lian B, Ji G. Beware Pathological Findings of the Stomach in Patients Undergoing Bariatric Surgery: a Systematic Review and Meta-analysis. *Obes Surg* 2021; **31**: 337-342 [PMID: 33047288 DOI: 10.1007/s11695-020-05029-7]

146 **Mocanu V**, Dang JT, Switzer N, Skubleny D, Shi X, de Gara C, Birch DW, Karmali S. The Effect of Helicobacter pylori on Postoperative Outcomes in Patients Undergoing Bariatric Surgery: a Systematic Review and Meta-analysis. *Obes Surg* 2018; **28**: 567-573 [PMID: 29159552 DOI: 10.1007/s11695-017-3024-8]

147 **Smelt HJM**, Smulders JF, Gilissen LPL, Said M, Ugale S, Pouwels S. Influence of Helicobacter pylori infection on gastrointestinal symptoms and complications in bariatric surgery patients: a review and meta-analysis. *Surg Obes Relat Dis* 2018; **14**: 1645-1657 [PMID: 30172695 DOI: 10.1016/j.soard.2018.06.020]

148 **Soresi M**, Cabibi D, Giglio RV, Martorana S, Guercio G, Porcasi R, Terranova A, Lazzaro LA, Emma MR, Augello G, Cervello M, Pantuso G, Montalto G, Giannitrapani L. The Prevalence of NAFLD and Fibrosis in Bariatric Surgery Patients and the Reliability of Noninvasive Diagnostic Methods. *Biomed Res Int* 2020; **2020**: 5023157 [PMID: 32420347 DOI: 10.1155/2020/5023157]

149 **Barbois S**, Arvieux C, Leroy V, Reche F, Stürm N, Borel AL. Benefit-risk of intraoperative liver biopsy during bariatric surgery: review and perspectives. *Surg Obes Relat Dis* 2017; **13**: 1780-1786 [PMID: 28935200 DOI: 10.1016/j.soard.2017.07.032]

150 **Younossi ZM**, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, Qiu Y, Burns L, Afendy A, Nader F. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. *J Hepatol* 2019; **71**: 793-801 [PMID: 31279902 DOI: 10.1016/j.jhep.2019.06.021]

151 **Bower G**, Toma T, Harling L, Jiao LR, Efthimiou E, Darzi A, Athanasiou T, Ashrafian H. Bariatric Surgery and Non-Alcoholic Fatty Liver Disease: a Systematic Review of Liver Biochemistry and Histology. *Obes Surg* 2015; **25**: 2280-2289 [PMID: 25917981 DOI: 10.1007/s11695-015-1691-x]

152 **Fakhry TK**, Mhaskar R, Schwitalla T, Muradova E, Gonzalvo JP, Murr MM. Bariatric surgery improves nonalcoholic fatty liver disease: a contemporary systematic review and meta-analysis. *Surg Obes Relat Dis* 2019; **15**: 502-511 [PMID: 30683512 DOI: 10.1016/j.soard.2018.12.002]

153 **Lee Y**, Doumouras AG, Yu J, Brar K, Banfield L, Gmora S, Anvari M, Hong D. Complete Resolution of Nonalcoholic Fatty Liver Disease After Bariatric Surgery: A Systematic Review and Meta-analysis. *Clin Gastroenterol Hepatol* 2019; **17**: 1040-1060.e11 [PMID: 30326299 DOI: 10.1016/j.cgh.2018.10.017]

154 **Baldwin D**, Chennakesavalu M, Gangemi A. Systematic review and meta-analysis of Roux-en-Y gastric bypass against laparoscopic sleeve gastrectomy for amelioration of NAFLD using four criteria. *Surg Obes Relat Dis* 2019; **15**: 2123-2130 [PMID: 31711944 DOI: 10.1016/j.soard.2019.09.060]

155 **Yang PC**, Wang CS, An ZY. Correction: a murine model of ulcerative colitis: induced with sinusitis-derived superantigen and food allergen. BMC Gastroenterol. 2005, 5:6. *BMC Gastroenterol* 2006; **6**: 23 [PMID: 16899127 DOI: 10.1186/s12876-020-01400-1]

156 **Netanel C**, Goitein D, Rubin M, Kleinbaum Y, Katsherginsky S, Hermon H, Tsaraf K, Tachlytski I, Herman A, Safran M, Ben-Ari Z. The impact of bariatric surgery on nonalcoholic fatty liver disease as measured using non-invasive tests. *Am J Surg* 2021; **222**: 214-219 [PMID: 33309037 DOI: 10.1016/j.amjsurg.2020.11.045]

157 **Atri A**, Jiwanmall SA, Nandyal MB, Kattula D, Paravathareddy S, Paul TV, Thomas N, Kapoor N. The Prevalence and Predictors of Non-alcoholic Fatty Liver Disease in Morbidly Obese Women - A Cross-sectional Study from Southern India. *Eur Endocrinol* 2020; **16**: 152-155 [PMID: 33117448 DOI: 10.17925/EE.2020.16.2.152]

158 **Petrick A**, Benotti P, Wood GC, Still CD, Strodel WE, Gabrielsen J, Rolston D, Chu X, Argyropoulos G, Ibele A, Gerhard GS. Utility of Ultrasound, Transaminases, and Visual Inspection to Assess Nonalcoholic Fatty Liver Disease in Bariatric Surgery Patients. *Obes Surg* 2015; **25**: 2368-2375 [PMID: 26003548 DOI: 10.1007/s11695-015-1707-6]

159 **Campos GM**, Bambha K, Vittinghoff E, Rabl C, Posselt AM, Ciovica R, Tiwari U, Ferrel L, Pabst M, Bass NM, Merriman RB. A clinical scoring system for predicting nonalcoholic steatohepatitis in morbidly obese patients. *Hepatology* 2008; **47**: 1916-1923 [PMID: 18433022 DOI: 10.1002/hep.22241]

160 **Shin WG**, Park SH, Jun SY, Jung JO, Moon JH, Kim JP, Kim KO, Park CH, Hahn TH, Yoo KS, Kim JH, Park CK. Simple tests to predict hepatic fibrosis in nonalcoholic chronic liver diseases. *Gut Liver* 2007; **1**: 145-150 [PMID: 20485631 DOI: 10.5009/gnl.2007.1.2.145]

161 **Sterling RK**, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, S Sulkowski M, Torriani FJ, Dieterich DT, Thomas DL, Messinger D, Nelson M; APRICOT Clinical Investigators. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. *Hepatology* 2006; **43**: 1317-1325 [PMID: 16729309 DOI: 10.1002/hep.21178]

162 **Angulo P**, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, Enders F, Saksena S, Burt AD, Bida JP, Lindor K, Sanderson SO, Lenzi M, Adams LA, Kench J, Therneau TM, Day CP. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. *Hepatology* 2007; **45**: 846-854 [PMID: 17393509 DOI: 10.1002/hep.21496]

163 **Harrison SA**, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. *Gut* 2008; **57**: 1441-1447 [PMID: 18390575 DOI: 10.1136/gut.2007.146019]

164 **Forns X**, Ampurdanès S, Llovet JM, Aponte J, Quintó L, Martínez-Bauer E, Bruguera M, Sánchez-Tapias JM, Rodés J. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. *Hepatology* 2002; **36**: 986-992 [PMID: 12297848 DOI: 10.1053/jhep.2002.36128]

165 **Meneses D**, Olveira A, Corripio R, Del Carmen Méndez M, Romero M, Calvo-Viñuelas I, Herranz L, Vicent D, de-Cos-Blanco AI. Performance of Noninvasive Liver Fibrosis Scores in the Morbid Obese Patient, Same Scores but Different Thresholds. *Obes Surg* 2020; **30**: 2538-2546 [PMID: 32157523 DOI: 10.1007/s11695-020-04509-0]

166 **Rath MM**, Panigrahi MK, Pattnaik K, Bhuyan P, Kar SK, Misra B, Misra D, Meher C, Agrawal O, Rath J, Singh SP. Histological Evaluation of Non-alcoholic Fatty Liver Disease and Its Correlation with Different Noninvasive Scoring Systems with Special Reference to Fibrosis: A Single Center Experience. *J Clin Exp Hepatol* 2016; **6**: 291-296 [PMID: 28003718 DOI: 10.1016/j.jceh.2016.08.006]

167 **Puthenpura MM**, Patel V, Fam J, Katz L, Tichansky DS, Myers S. The Use of Transient Elastography Technology in the Bariatric Patient: a Review of the Literature. *Obes Surg* 2020; **30**: 5108-5116 [PMID: 32981002 DOI: 10.1007/s11695-020-05002-4]

168 **Jamialahmadi T**, Nematy M, Jangjoo A, Goshayeshi L, Rezvani R, Ghaffarzadegan K, Nooghabi MJ, Shalchian P, Zangui M, Javid Z, Doaei S, Rajabzadeh F. Measurement of Liver Stiffness with 2D-Shear Wave Elastography (2D-SWE) in Bariatric Surgery Candidates Reveals Acceptable Diagnostic Yield Compared to Liver Biopsy. *Obes Surg* 2019; **29**: 2585-2592 [PMID: 31077025 DOI: 10.1007/s11695-019-03889-2]

169 **Praveenraj P**, Gomes RM, Basuraju S, Kumar S, Senthilnathan P, Parathasarathi R, Rajapandian S, Palanivelu C. Preliminary Evaluation of Acoustic Radiation Force Impulse Shear Wave Imaging to Detect Hepatic Fibrosis in Morbidly Obese Patients Before Bariatric Surgery. *J Laparoendosc Adv Surg Tech A* 2016; **26**: 192-195 [PMID: 26895403 DOI: 10.1089/lap.2015.0396]

170 **Allen AM**, Shah VH, Therneau TM, Venkatesh SK, Mounajjed T, Larson JJ, Mara KC, Schulte PJ, Kellogg TA, Kendrick ML, McKenzie TJ, Greiner SM, Li J, Glaser KJ, Wells ML, Chen J, Ehman RL, Yin M. The Role of Three-Dimensional Magnetic Resonance Elastography in the Diagnosis of Nonalcoholic Steatohepatitis in Obese Patients Undergoing Bariatric Surgery. *Hepatology* 2020; **71**: 510-521 [PMID: 30582669 DOI: 10.1002/hep.30483]

171 **Garofalo C**, Borrelli S, Minutolo R, Chiodini P, De Nicola L, Conte G. A systematic review and meta-analysis suggests obesity predicts onset of chronic kidney disease in the general population. *Kidney Int* 2017; **91**: 1224-1235 [PMID: 28187985 DOI: 10.1016/j.kint.2016.12.013]

172 **Fu H**, Liu S, Bastacky SI, Wang X, Tian XJ, Zhou D. Diabetic kidney diseases revisited: A new perspective for a new era. *Mol Metab* 2019; **30**: 250-263 [PMID: 31767176 DOI: 10.1016/j.molmet.2019.10.005]

173 **Afkarian M**, Zelnick LR, Hall YN, Heagerty PJ, Tuttle K, Weiss NS, de Boer IH. Clinical Manifestations of Kidney Disease Among US Adults With Diabetes, 1988-2014. *JAMA* 2016; **316**: 602-610 [PMID: 27532915 DOI: 10.1001/jama.2016.10924]

174 **American Diabetes Association**. Addendum. 11. Microvascular Complications and Foot Care: *Standards of Medical Care in Diabetes-2021*: Diabetes Care 2021;44(Suppl. 1):S151-S167. *Diabetes Care* 2021 [PMID: 34135018 DOI: 10.2337/dc21-S011]

175 **Stevens PE**, Levin A; Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. *Ann Intern Med* 2013; **158**: 825-830 [PMID: 23732715 DOI: 10.7326/0003-4819-158-11-201306040-00007]

176 **Friedman AN**, Moe S, Fadel WF, Inman M, Mattar SG, Shihabi Z, Quinney SK. Predicting the glomerular filtration rate in bariatric surgery patients. *Am J Nephrol* 2014; **39**: 8-15 [PMID: 24356416 DOI: 10.1159/000357231]

177 **Chang AR**, Zafar W, Grams ME. Kidney Function in Obesity-Challenges in Indexing and Estimation. *Adv Chronic Kidney Dis* 2018; **25**: 31-40 [PMID: 29499884 DOI: 10.1053/j.ackd.2017.10.007]

178 **Chang AR**, George J, Levey AS, Coresh J, Grams ME, Inker LA. Performance of Glomerular Filtration Rate Estimating Equations Before and After Bariatric Surgery. *Kidney Med* 2020; **2**: 699-706.e1 [PMID: 33319195 DOI: 10.1016/j.xkme.2020.08.008]

179 **Chuah LL**, Miras AD, Perry LM, Frankel AH, Towey DJ, Al-Mayahi Z, Svensson W, le Roux CW. Measurement of glomerular filtration rate in patients undergoing obesity surgery. *BMC Nephrol* 2018; **19**: 383 [PMID: 30594245 DOI: 10.1186/s12882-018-1188-7]

180 **Friedman AN**, Cohen RV. Bariatric surgery as a renoprotective intervention. *Curr Opin Nephrol Hypertens* 2019; **28**: 537-544 [PMID: 31436552 DOI: 10.1097/MNH.0000000000000539]

181 **Docherty NG**, le Roux CW. Bariatric surgery for the treatment of chronic kidney disease in obesity and type 2 diabetes mellitus. *Nat Rev Nephrol* 2020; **16**: 709-720 [PMID: 32778788 DOI: 10.1038/s41581-020-0323-4]

182 **Friedman AN**, Wang J, Wahed AS, Docherty NG, Fennern E, Pomp A, Purnell JQ, le Roux CW, Wolfe B. The Association Between Kidney Disease and Diabetes Remission in Bariatric Surgery Patients With Type 2 Diabetes. *Am J Kidney Dis* 2019; **74**: 761-770 [PMID: 31331758 DOI: 10.1053/j.ajkd.2019.05.013]

183 **Bilha SC**, Nistor I, Nedelcu A, Kanbay M, Scripcariu V, Timofte D, Siriopol D, Covic A. The Effects of Bariatric Surgery on Renal Outcomes: a Systematic Review and Meta-analysis. *Obes Surg* 2018; **28**: 3815-3833 [PMID: 30054877 DOI: 10.1007/s11695-018-3416-4]

184 **Hansel B**, Arapis K, Kadouch D, Ledoux S, Coupaye M, Msika S, Vrtovsnik F, Marre M, Boutten A, Cherifi B, Cambos S, Beslay M, Courie R, Roussel R. Severe Chronic Kidney Disease Is Associated with a Lower Efficiency of Bariatric Surgery. *Obes Surg* 2019; **29**: 1514-1520 [PMID: 30685835 DOI: 10.1007/s11695-019-03703-z]

185 **Barzin M**, Mousapour P, Khalaj A, Mahdavi M, Valizadeh M, Hosseinpanah F. The Relationship Between Preoperative Kidney Function and Weight Loss After Bariatric Surgery in Patients with Estimated Glomerular Filtration Rate ≥ 30 mL/min: Tehran Obesity Treatment Study. *Obes Surg* 2020; **30**: 1859-1865 [PMID: 31953746 DOI: 10.1007/s11695-020-04407-5]

186 **Turgeon NA**, Perez S, Mondestin M, Davis SS, Lin E, Tata S, Kirk AD, Larsen CP, Pearson TC, Sweeney JF. The impact of renal function on outcomes of bariatric surgery. *J Am Soc Nephrol* 2012; **23**: 885-894 [PMID: 22383694 DOI: 10.1681/ASN.2011050476]

187 **Cohen JB**, Tewksbury CM, Torres Landa S, Williams NN, Dumon KR. National Postoperative Bariatric Surgery Outcomes in Patients with Chronic Kidney Disease and End-Stage Kidney Disease. *Obes Surg* 2019; **29**: 975-982 [PMID: 30443719 DOI: 10.1007/s11695-018-3604-2]

188 **Canales BK**, Gonzalez RD. Kidney stone risk following Roux-en-Y gastric bypass surgery. *Transl Androl Urol* 2014; **3**: 242-249 [PMID: 25473624 DOI: 10.3978/j.issn.2223-4683.2014.06.02]

189 Correction to: *A Murine Model of Volumetric Muscle Loss and a Regenerative Medicine Approach for Tissue Replacement* by Sicari BM, Agrawal V, Siu BF, Medberry CJ, Dearth CL, Turner NJ, Badylak SF.Tissue Eng Part A 2012;18(19-20):1941-1948. DOI: 10.1089/ten.tea.2012.0475. *Tissue Eng Part A* 2018; **24**: 861 [PMID: 31329760 DOI: 10.1089/ten.tea.2012.0475.correction]

190 **Upala S**, Jaruvongvanich V, Sanguankeo A. Risk of nephrolithiasis, hyperoxaluria, and calcium oxalate supersaturation increased after Roux-en-Y gastric bypass surgery: a systematic review and meta-analysis. *Surg Obes Relat Dis* 2016; **12**: 1513-1521 [PMID: 27396545 DOI: 10.1016/j.soard.2016.04.004]

191 **Bhatti UH**, Duffy AJ, Roberts KE, Shariff AH. Nephrolithiasis after bariatric surgery: A review of pathophysiologic mechanisms and procedural risk. *Int J Surg* 2016; **36**: 618-623 [PMID: 27847289 DOI: 10.1016/j.ijsu.2016.11.025]

192 **Mishra T**, Shapiro JB, Ramirez L, Kallies KJ, Kothari SN, Londergan TA. Nephrolithiasis after bariatric surgery: A comparison of laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy. *Am J Surg* 2020; **219**: 952-957 [PMID: 31564408 DOI: 10.1016/j.amjsurg.2019.09.010]

193 **Gong M**, Wen S, Nguyen T, Wang C, Jin J, Zhou L. Converging Relationships of Obesity and Hyperuricemia with Special Reference to Metabolic Disorders and Plausible Therapeutic Implications. *Diabetes Metab Syndr Obes* 2020; **13**: 943-962 [PMID: 32280253 DOI: 10.2147/DMSO.S232377]

194 **Ali N**, Perveen R, Rahman S, Mahmood S, Rahman S, Islam S, Haque T, Sumon AH, Kathak RR, Molla NH, Islam F, Mohanto NC, Nurunnabi SM, Ahmed S, Rahman M. Prevalence of hyperuricemia and the relationship between serum uric acid and obesity: A study on Bangladeshi adults. *PLoS One* 2018; **13**: e0206850 [PMID: 30383816 DOI: 10.1371/journal.pone.0206850]

195 **Yeo C**, Kaushal S, Lim B, Syn N, Oo AM, Rao J, Koura A, Yeo D. Impact of bariatric surgery on serum uric acid levels and the incidence of gout-A meta-analysis. *Obes Rev* 2019; **20**: 1759-1770 [PMID: 31468681 DOI: 10.1111/obr.12940]

196 **Romero-Talamás H**, Daigle CR, Aminian A, Corcelles R, Brethauer SA, Schauer PR. The effect of bariatric surgery on gout: a comparative study. *Surg Obes Relat Dis* 2014; **10**: 1161-1165 [PMID: 24935177 DOI: 10.1016/j.soard.2014.02.025]

197 **Friedman JE**, Dallal RM, Lord JL. Gouty attacks occur frequently in postoperative gastric bypass patients. *Surg Obes Relat Dis* 2008; **4**: 11-13 [PMID: 18065292 DOI: 10.1016/j.soard.2007.09.012]

198 **Antoniou SA,** Anastasiadou A, Antoniou GA, Granderath FA, Kafatos A. Preoperative nutritional counseling vs standard care prior to bariatric surgery: Effects on postoperative weight loss. *Eur Surg* 2017; **49**: 113-117 [DOI: 10.1007/s10353-016-0459-4]

199 **Tewksbury C**, Williams NN, Dumon KR, Sarwer DB. Preoperative Medical Weight Management in Bariatric Surgery: a Review and Reconsideration. *Obes Surg* 2017; **27**: 208-214 [PMID: 27761723 DOI: 10.1007/s11695-016-2422-7]

200 **Sherf-Dagan S**, Sinai T, Goldenshluger A, Globus I, Kessler Y, Schweiger C, Ben-Porat T. Nutritional Assessment and Preparation for Adult Bariatric Surgery Candidates: Clinical Practice. *Adv Nutr* 2021; **12**: 1020-1031 [PMID: 33040143 DOI: 10.1093/advances/nmaa121]

201 **Lewis CA**, de Jersey S, Seymour M, Hopkins G, Hickman I, Osland E. Iron, Vitamin B12, Folate and Copper Deficiency After Bariatric Surgery and the Impact on Anaemia: a Systematic Review. *Obes Surg* 2020; **30**: 4542-4591 [PMID: 32785814 DOI: 10.1007/s11695-020-04872-y]

202 **Lewis CA**, de Jersey S, Hopkins G, Hickman I, Osland E. Does Bariatric Surgery Cause Vitamin A, B1, C or E Deficiency? A Systematic Review. *Obes Surg* 2018; **28**: 3640-3657 [PMID: 30120641 DOI: 10.1007/s11695-018-3392-8]

203 **Benotti PN**, Wood GC, Still CD, Gerhard GS, Rolston DD, Bistrian BR. Metabolic surgery and iron homeostasis. *Obes Rev* 2019; **20**: 612-620 [PMID: 30589498 DOI: 10.1111/obr.12811]

204 **Flancbaum L**, Belsley S, Drake V, Colarusso T, Tayler E. Preoperative nutritional status of patients undergoing Roux-en-Y gastric bypass for morbid obesity. *J Gastrointest Surg* 2006; **10**: 1033-1037 [PMID: 16843874 DOI: 10.1016/j.gassur.2006.03.004]

205 **Schweiger C**, Weiss R, Berry E, Keidar A. Nutritional deficiencies in bariatric surgery candidates. *Obes Surg* 2010; **20**: 193-197 [PMID: 19876694 DOI: 10.1007/s11695-009-0008-3]

206 **Toh SY**, Zarshenas N, Jorgensen J. Prevalence of nutrient deficiencies in bariatric patients. *Nutrition* 2009; **25**: 1150-1156 [PMID: 19487104 DOI: 10.1016/j.nut.2009.03.012]

207 **Al-Mutawa A**, Anderson AK, Alsabah S, Al-Mutawa M. Nutritional Status of Bariatric Surgery Candidates. *Nutrients* 2018; **10** [PMID: 29324643 DOI: 10.3390/nu10010067]

208 **Zimmermann MB**, Zeder C, Muthayya S, Winichagoon P, Chaouki N, Aeberli I, Hurrell RF. Adiposity in women and children from transition countries predicts decreased iron absorption, iron deficiency and a reduced response to iron fortification. *Int J Obes (Lond)* 2008; **32**: 1098-1104 [PMID: 18427564 DOI: 10.1038/ijo.2008.43]

209 **Haidari F**, Abiri B, Haghighizadeh MH, Kayedani GA, Birgani NK. Association of Hematological Parameters with Obesity- Induced Inflammation Among Young Females in Ahvaz, South-West of Iran. *Int J Prev Med* 2020; **11**: 55 [PMID: 32577185 DOI: 10.4103/ijpvm.IJPVM\_35\_18]

210 **Bassuk SS**, Rifai N, Ridker PM. High-sensitivity C-reactive protein: clinical importance. *Curr Probl Cardiol* 2004; **29**: 439-493 [PMID: 15258556]

211 **Cappellini MD**, Musallam KM, Taher AT. Iron deficiency anaemia revisited. *J Intern Med* 2020; **287**: 153-170 [PMID: 31665543 DOI: 10.1111/joim.13004]

212 **Madu AJ**, Ughasoro MD. Anaemia of Chronic Disease: An In-Depth Review. *Med Princ Pract* 2017; **26**: 1-9 [PMID: 27756061 DOI: 10.1159/000452104]

213 **Jericó C**, Bretón I, García Ruiz de Gordejuela A, de Oliveira AC, Rubio MÁ, Tinahones FJ, Vidal J, Vilarrasa N. [Diagnosis and treatment of iron deficiency, with or without anemia, before and after bariatric surgery]. *Endocrinol Nutr* 2016; **63**: 32-42 [PMID: 26611153 DOI: 10.1016/j.endonu.2015.09.003]

214 **Benotti PN**, Wood GC, Kaberi-Otarod J, Still CD, Gerhard GS, Bistrian BR. New concepts in the diagnosis and management approach to iron deficiency in candidates for metabolic surgery: should we change our practice? *Surg Obes Relat Dis* 2020; **16**: 2074-2081 [PMID: 33011074 DOI: 10.1016/j.soard.2020.08.018]

215 **Ernst B**, Thurnheer M, Schmid SM, Schultes B. Evidence for the necessity to systematically assess micronutrient status prior to bariatric surgery. *Obes Surg* 2009; **19**: 66-73 [PMID: 18491197 DOI: 10.1007/s11695-008-9545-4]

216 **Lefebvre P**, Letois F, Sultan A, Nocca D, Mura T, Galtier F. Nutrient deficiencies in patients with obesity considering bariatric surgery: a cross-sectional study. *Surg Obes Relat Dis* 2014; **10**: 540-546 [PMID: 24630922 DOI: 10.1016/j.soard.2013.10.003]

217 **Ben-Porat T**, Weiss R, Sherf-Dagan S, Nabulsi N, Maayani A, Khalaileh A, Abed S, Brodie R, Harari R, Mintz Y, Pikarsky AJ, Elazary R. Nutritional Deficiencies in Patients with Severe Obesity before Bariatric Surgery: What Should Be the Focus During the Preoperative Assessment? *J Acad Nutr Diet* 2020; **120**: 874-884 [PMID: 31892499 DOI: 10.1016/j.jand.2019.10.017]

218 **Frame-Peterson LA**, Megill RD, Carobrese S, Schweitzer M. Nutrient Deficiencies Are Common Prior to Bariatric Surgery. *Nutr Clin Pract* 2017; **32**: 463-469 [PMID: 28636832 DOI: 10.1177/0884533617712701]

219 **Yang W**, Cai X, Wu H, Ji L. Associations between metformin use and vitamin B12 levels, anemia, and neuropathy in patients with diabetes: a meta-analysis. *J Diabetes* 2019; **11**: 729-743 [PMID: 30615306 DOI: 10.1111/1753-0407.12900]

220 **Chapman LE**, Darling AL, Brown JE. Association between metformin and vitamin B12 deficiency in patients with type 2 diabetes: A systematic review and meta-analysis. *Diabetes Metab* 2016; **42**: 316-327 [PMID: 27130885 DOI: 10.1016/j.diabet.2016.03.008]

221 **Guan B**, Yang J, Chen Y, Yang W, Wang C. Nutritional Deficiencies in Chinese Patients Undergoing Gastric Bypass and Sleeve Gastrectomy: Prevalence and Predictors. *Obes Surg* 2018; **28**: 2727-2736 [PMID: 29754386 DOI: 10.1007/s11695-018-3225-9]

222 **Shipton MJ**, Johal NJ, Dutta N, Slater C, Iqbal Z, Ahmed B, Ammori BJ, Senapati S, Akhtar K, Summers LKM, New JP, Soran H, Adam S, Syed AA. Haemoglobin and Hematinic Status Before and After Bariatric Surgery over 4 years of Follow-Up. *Obes Surg* 2021; **31**: 682-693 [PMID: 32875517 DOI: 10.1007/s11695-020-04943-0]

223 **O'Kane M**, Parretti HM, Pinkney J, Welbourn R, Hughes CA, Mok J, Walker N, Thomas D, Devin J, Coulman KD, Pinnock G, Batterham RL, Mahawar KK, Sharma M, Blakemore AI, McMillan I, Barth JH. British Obesity and Metabolic Surgery Society Guidelines on perioperative and postoperative biochemical monitoring and micronutrient replacement for patients undergoing bariatric surgery-2020 update. *Obes Rev* 2020; **21**: e13087 [PMID: 32743907 DOI: 10.1111/obr.13087]

224 **Parrott J**, Frank L, Rabena R, Craggs-Dino L, Isom KA, Greiman L. American Society for Metabolic and Bariatric Surgery Integrated Health Nutritional Guidelines for the Surgical Weight Loss Patient 2016 Update: Micronutrients. *Surg Obes Relat Dis* 2017; **13**: 727-741 [PMID: 28392254 DOI: 10.1016/j.soard.2016.12.018]

225 **Majumder S**, Soriano J, Louie Cruz A, Dasanu CA. Vitamin B12 deficiency in patients undergoing bariatric surgery: preventive strategies and key recommendations. *Surg Obes Relat Dis* 2013; **9**: 1013-1019 [PMID: 24091055 DOI: 10.1016/j.soard.2013.04.017]

226 **Smelt HJ**, Pouwels S, Smulders JF. Different Supplementation Regimes to Treat Perioperative Vitamin B12 Deficiencies in Bariatric Surgery: a Systematic Review. *Obes Surg* 2017; **27**: 254-262 [PMID: 27838841 DOI: 10.1007/s11695-016-2449-9]

227 **Komorniak N**, Szczuko M, Kowalewski B, Stachowska E. Nutritional Deficiencies, Bariatric Surgery, and Serum Homocysteine Level: Review of Current Literature. *Obes Surg* 2019; **29**: 3735-3742 [PMID: 31471768 DOI: 10.1007/s11695-019-04100-2]

228 **Langan RC**, Goodbred AJ. Vitamin B12 Deficiency: Recognition and Management. *Am Fam Physician* 2017; **96**: 384-389 [PMID: 28925645]

229 **Vimaleswaran KS**, Berry DJ, Lu C, Tikkanen E, Pilz S, Hiraki LT, Cooper JD, Dastani Z, Li R, Houston DK, Wood AR, Michaëlsson K, Vandenput L, Zgaga L, Yerges-Armstrong LM, McCarthy MI, Dupuis J, Kaakinen M, Kleber ME, Jameson K, Arden N, Raitakari O, Viikari J, Lohman KK, Ferrucci L, Melhus H, Ingelsson E, Byberg L, Lind L, Lorentzon M, Salomaa V, Campbell H, Dunlop M, Mitchell BD, Herzig KH, Pouta A, Hartikainen AL; Genetic Investigation of Anthropometric Traits-GIANT Consortium, Streeten EA, Theodoratou E, Jula A, Wareham NJ, Ohlsson C, Frayling TM, Kritchevsky SB, Spector TD, Richards JB, Lehtimäki T, Ouwehand WH, Kraft P, Cooper C, März W, Power C, Loos RJ, Wang TJ, Järvelin MR, Whittaker JC, Hingorani AD, Hyppönen E. Causal relationship between obesity and vitamin D status: bi-directional Mendelian randomization analysis of multiple cohorts. *PLoS Med* 2013; **10**: e1001383 [PMID: 23393431 DOI: 10.1371/journal.pmed.1001383]

230 **Cabral JA**, Souza GP, Nascimento JA, Simoneti LF, Marchese C, Sales-Peres SH. Impact of vitamin d and calcium deficiency in the bones of patients undergoing bariatric surgery: a systematic review. *Arq Bras Cir Dig* 2016; **29** Suppl 1: 120-123 [PMID: 27683792 DOI: 10.1590/0102-6720201600S10029]

231 **Chakhtoura MT**, Nakhoul NN, Shawwa K, Mantzoros C, El Hajj Fuleihan GA. Hypovitaminosis D in bariatric surgery: A systematic review of observational studies. *Metabolism* 2016; **65**: 574-585 [PMID: 26805016 DOI: 10.1016/j.metabol.2015.12.004]

232 **Compher CW**, Badellino KO, Boullata JI. Vitamin D and the bariatric surgical patient: a review. *Obes Surg* 2008; **18**: 220-224 [PMID: 18176832 DOI: 10.1007/s11695-007-9289-6]

233 **Liu C**, Wu D, Zhang JF, Xu D, Xu WF, Chen Y, Liu BY, Li P, Li L. Changes in Bone Metabolism in Morbidly Obese Patients After Bariatric Surgery: A Meta-Analysis. *Obes Surg* 2016; **26**: 91-97 [PMID: 25982806 DOI: 10.1007/s11695-015-1724-5]

234 **Chakhtoura MT**, Nakhoul N, Akl EA, Mantzoros CS, El Hajj Fuleihan GA. Guidelines on vitamin D replacement in bariatric surgery: Identification and systematic appraisal. *Metabolism* 2016; **65**: 586-597 [PMID: 26833101 DOI: 10.1016/j.metabol.2015.12.013]

235 **Schiavo L**, Pilone V, Rossetti G, Romano M, Pieretti G, Schneck AS, Iannelli A. Correcting micronutrient deficiencies before sleeve gastrectomy may be useful in preventing early postoperative micronutrient deficiencies. *Int J Vitam Nutr Res* 2019; **89**: 22-28 [PMID: 30694119 DOI: 10.1024/0300-9831/a000532]

236 **Johnson LM**, Ikramuddin S, Leslie DB, Slusarek B, Killeen AA. Analysis of vitamin levels and deficiencies in bariatric surgery patients: a single-institutional analysis. *Surg Obes Relat Dis* 2019; **15**: 1146-1152 [PMID: 31202681 DOI: 10.1016/j.soard.2019.04.028]

237 **Sherf-Dagan S**, Goldenshluger A, Azran C, Sakran N, Sinai T, Ben-Porat T. Vitamin K-what is known regarding bariatric surgery patients: a systematic review. *Surg Obes Relat Dis* 2019; **15**: 1402-1413 [PMID: 31353233 DOI: 10.1016/j.soard.2019.05.031]

238 **Guan B**, Chen Y, Yang J, Yang W, Wang C. Effect of Bariatric Surgery on Thyroid Function in Obese Patients: a Systematic Review and Meta-Analysis. *Obes Surg* 2017; **27**: 3292-3305 [PMID: 29039052 DOI: 10.1007/s11695-017-2965-2]

239 **Neves JS**, Souteiro P, Oliveira SC, Pedro J, Magalhães D, Guerreiro V, Costa MM, Bettencourt-Silva R, Santos AC, Queirós J, Varela A, Freitas P, Carvalho D; AMTCO Group. Preoperative thyroid function and weight loss after bariatric surgery. *Int J Obes (Lond)* 2019; **43**: 432-436 [PMID: 29769703 DOI: 10.1038/s41366-018-0071-8]

240 **Xia MF**, Chang XX, Zhu XP, Yan HM, Shi CY, Wu W, Zhong M, Zeng HL, Bian H, Wu HF, Gao X. Preoperative Thyroid Autoimmune Status and Changes in Thyroid Function and Body Weight After Bariatric Surgery. *Obes Surg* 2019; **29**: 2904-2911 [PMID: 31256358 DOI: 10.1007/s11695-019-03910-8]

241 **Lammert A**, Nittka S, Otto M, Schneider-Lindner V, Kemmer A, Krämer BK, Birck R, Hammes HP, Benck U. Performance of the 1 mg dexamethasone suppression test in patients with severe obesity. *Obesity (Silver Spring)* 2016; **24**: 850-855 [PMID: 26948683 DOI: 10.1002/oby.21442]

242 **Javorsky BR**, Carroll TB, Tritos NA, Salvatori R, Heaney AP, Fleseriu M, Biller BM, Findling JW. Discovery of Cushing's Syndrome After Bariatric Surgery: Multicenter Series of 16 Patients. *Obes Surg* 2015; **25**: 2306-2313 [PMID: 25917980 DOI: 10.1007/s11695-015-1681-z]

243 **Borsoi L**, Ludvik B, Prager G, Luger A, Riedl M. Cushing's syndrome in a morbidly obese patient undergoing evaluation before bariatric surgery. *Obes Facts* 2014; **7**: 191-196 [PMID: 24903206 DOI: 10.1159/000363260]

244 **Janković D**, Wolf P, Anderwald CH, Winhofer Y, Promintzer-Schifferl M, Hofer A, Langer F, Prager G, Ludvik B, Gessl A, Luger A, Krebs M. Prevalence of endocrine disorders in morbidly obese patients and the effects of bariatric surgery on endocrine and metabolic parameters. *Obes Surg* 2012; **22**: 62-69 [PMID: 22052199 DOI: 10.1007/s11695-011-0545-4]

245 **Kapoor N**, Job V, Jayaseelan L, Rajaratnam S. Spot urine cortisol-creatinine ratio - A useful screening test in the diagnosis of Cushing's syndrome. *Indian J Endocrinol Metab* 2012; **16**: S376-S377 [PMID: 23565435 DOI: 10.4103/2230-8210.104099]

246 **Shawe J**, Ceulemans D, Akhter Z, Neff K, Hart K, Heslehurst N, Štotl I, Agrawal S, Steegers-Theunissen R, Taheri S, Greenslade B, Rankin J, Huda B, Douek I, Galjaard S, Blumenfeld O, Robinson A, Whyte M, Mathews E, Devlieger R. Pregnancy after bariatric surgery: Consensus recommendations for periconception, antenatal and postnatal care. *Obes Rev* 2019; **20**: 1507-1522 [PMID: 31419378 DOI: 10.1111/obr.12927]

247 **Akhter Z**, Rankin J, Ceulemans D, Ngongalah L, Ackroyd R, Devlieger R, Vieira R, Heslehurst N. Pregnancy after bariatric surgery and adverse perinatal outcomes: A systematic review and meta-analysis. *PLoS Med* 2019; **16**: e1002866 [PMID: 31386658 DOI: 10.1371/journal.pmed.1002866]

248 **Kwong W**, Tomlinson G, Feig DS. Maternal and neonatal outcomes after bariatric surgery; a systematic review and meta-analysis: do the benefits outweigh the risks? *Am J Obstet Gynecol* 2018; **218**: 573-580 [PMID: 29454871 DOI: 10.1016/j.ajog.2018.02.003]

249 **Milone M**, De Placido G, Musella M, Sosa Fernandez LM, Sosa Fernandez LV, Campana G, Di Minno MN, Milone F. Incidence of Successful Pregnancy After Weight Loss Interventions in Infertile Women: a Systematic Review and Meta-Analysis of the Literature. *Obes Surg* 2016; **26**: 443-451 [PMID: 26661108 DOI: 10.1007/s11695-015-1998-7]

250 **Schlatter J**. Oral Contraceptives after Bariatric Surgery. *Obes Facts* 2017; **10**: 118-126 [PMID: 28433989 DOI: 10.1159/000449508]

251 **Skubleny D**, Switzer NJ, Gill RS, Dykstra M, Shi X, Sagle MA, de Gara C, Birch DW, Karmali S. The Impact of Bariatric Surgery on Polycystic Ovary Syndrome: a Systematic Review and Meta-analysis. *Obes Surg* 2016; **26**: 169-176 [PMID: 26431698 DOI: 10.1007/s11695-015-1902-5]

252 **Escobar-Morreale HF**, Santacruz E, Luque-Ramírez M, Botella Carretero JI. Prevalence of 'obesity-associated gonadal dysfunction' in severely obese men and women and its resolution after bariatric surgery: a systematic review and meta-analysis. *Hum Reprod Update* 2017; **23**: 390-408 [PMID: 28486593 DOI: 10.1093/humupd/dmx012]

253 **Li YJ**, Han Y, He B. Effects of bariatric surgery on obese polycystic ovary syndrome: a systematic review and meta-analysis. *Surg Obes Relat Dis* 2019; **15**: 942-950 [PMID: 31113751 DOI: 10.1016/j.soard.2019.03.032]

254 **Corona G**, Rastrelli G, Monami M, Saad F, Luconi M, Lucchese M, Facchiano E, Sforza A, Forti G, Mannucci E, Maggi M. Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. *Eur J Endocrinol* 2013; **168**: 829-843 [PMID: 23482592 DOI: 10.1530/EJE-12-0955]

255 **Corona G**, Monami M, Rastrelli G, Aversa A, Sforza A, Lenzi A, Forti G, Mannucci E, Maggi M. Type 2 diabetes mellitus and testosterone: a meta-analysis study. *Int J Androl* 2011; **34**: 528-540 [PMID: 20969599 DOI: 10.1111/j.1365-2605.2010.01117.x]

256 **Vos N**, Oussaada SM, Cooiman MI, Kleinendorst L, Ter Horst KW, Hazebroek EJ, Romijn JA, Serlie MJ, Mannens MMAM, van Haelst MM. Bariatric Surgery for Monogenic Non-syndromic and Syndromic Obesity Disorders. *Curr Diab Rep* 2020; **20**: 44 [PMID: 32729070 DOI: 10.1007/s11892-020-01327-7]

257 **Bell CG**, Walley AJ, Froguel P. The genetics of human obesity. *Nat Rev Genet* 2005; **6**: 221-234 [PMID: 15703762 DOI: 10.1038/nrg1556]

258 **Farooqi IS**, O'Rahilly S. Mutations in ligands and receptors of the leptin-melanocortin pathway that lead to obesity. *Nat Clin Pract Endocrinol Metab* 2008; **4**: 569-577 [PMID: 18779842 DOI: 10.1038/ncpendmet0966]

259 **Oswal A**, Yeo GS. The leptin melanocortin pathway and the control of body weight: lessons from human and murine genetics. *Obes Rev* 2007; **8**: 293-306 [PMID: 17578380 DOI: 10.1111/j.1467-789X.2007.00378.x]

260 **Kaur Y**, de Souza RJ, Gibson WT, Meyre D. A systematic review of genetic syndromes with obesity. *Obes Rev* 2017; **18**: 603-634 [PMID: 28346723 DOI: 10.1111/obr.12531]

261 **Butler MG**. Single Gene and Syndromic Causes of Obesity: Illustrative Examples. *Prog Mol Biol Transl Sci* 2016; **140**: 1-45 [PMID: 27288824 DOI: 10.1016/bs.pmbts.2015.12.003]

262 **Li Y**, Zhang H, Tu Y, Wang C, Di J, Yu H, Zhang P, Bao Y, Jia W, Yang J, Hu C. Monogenic Obesity Mutations Lead to Less Weight Loss After Bariatric Surgery: a 6-Year Follow-Up Study. *Obes Surg* 2019; **29**: 1169-1173 [PMID: 30719650 DOI: 10.1007/s11695-018-03623-4]

263 **Liu SY**, Wong SK, Lam CC, Ng EK. Bariatric surgery for Prader-Willi syndrome was ineffective in producing sustainable weight loss: Long term results for up to 10 years. *Pediatr Obes* 2020; **15**: e12575 [PMID: 31515962 DOI: 10.1111/ijpo.12575]

264 **Ramasamy S**, Joseph M, Jiwanmall SA, Kattula D, Nandyal MB, Abraham V, Samarasam I, Paravathareddy S, Paul TV, Rajaratnam S, Thomas N, Kapoor N. Obesity Indicators and Health-related Quality of Life - Insights from a Cohort of Morbidly Obese, Middle-aged South Indian Women. *Eur Endocrinol* 2020; **16**: 148-151 [PMID: 33117447 DOI: 10.17925/EE.2020.16.2.148]

265 **Jiwanmall SA**, Kattula D, Nandyal MB, Devika S, Kapoor N, Joseph M, Paravathareddy S, Shetty S, Paul TV, Rajaratnam S, Thomas N, Abraham V, Samarasam I. Psychiatric Burden in the Morbidly Obese in Multidisciplinary Bariatric Clinic in South India. *Indian J Psychol Med* 2018; **40**: 129-133 [PMID: 29962568 DOI: 10.4103/IJPSYM.IJPSYM\_187\_17]

266 **Sogg S**, Lauretti J, West-Smith L. Recommendations for the presurgical psychosocial evaluation of bariatric surgery patients. *Surg Obes Relat Dis* 2016; **12**: 731-749 [PMID: 27179400 DOI: 10.1016/j.soard.2016.02.008]

267 **Dawes AJ**, Maggard-Gibbons M, Maher AR, Booth MJ, Miake-Lye I, Beroes JM, Shekelle PG. Mental Health Conditions Among Patients Seeking and Undergoing Bariatric Surgery: A Meta-analysis. *JAMA* 2016; **315**: 150-163 [PMID: 26757464 DOI: 10.1001/jama.2015.18118]

268 **Lim RBC**, Zhang MWB, Ho RCM. Prevalence of All-Cause Mortality and Suicide among Bariatric Surgery Cohorts: A Meta-Analysis. *Int J Environ Res Public Health* 2018; **15** [PMID: 30021983 DOI: 10.3390/ijerph15071519]

269 **Adams TD**, Mehta TS, Davidson LE, Hunt SC. All-Cause and Cause-Specific Mortality Associated with Bariatric Surgery: A Review. *Curr Atheroscler Rep* 2015; **17**: 74 [PMID: 26496931 DOI: 10.1007/s11883-015-0551-4]

270 **Roizblatt A**, Roizblatt D, Soto-Aguilar B F. [Suicide risk after bariatric surgery]. *Rev Med Chil* 2016; **144**: 1171-1176 [PMID: 28060979 DOI: 10.4067/S0034-98872016000900011]

271 **Castaneda D**, Popov VB, Wander P, Thompson CC. Risk of Suicide and Self-harm Is Increased After Bariatric Surgery-a Systematic Review and Meta-analysis. *Obes Surg* 2019; **29**: 322-333 [PMID: 30343409 DOI: 10.1007/s11695-018-3493-4]

272 **De Luca M**, Angrisani L, Himpens J, Busetto L, Scopinaro N, Weiner R, Sartori A, Stier C, Lakdawala M, Bhasker AG, Buchwald H, Dixon J, Chiappetta S, Kolberg HC, Frühbeck G, Sarwer DB, Suter M, Soricelli E, Blüher M, Vilallonga R, Sharma A, Shikora S. Indications for Surgery for Obesity and Weight-Related Diseases: Position Statements from the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO). *Obes Surg* 2016; **26**: 1659-1696 [PMID: 27412673 DOI: 10.1007/s11695-016-2271-4]

273 **David LA**, Sijercic I, Cassin SE. Preoperative and post-operative psychosocial interventions for bariatric surgery patients: A systematic review. *Obes Rev* 2020; **21**: e12926 [PMID: 31970925 DOI: 10.1111/obr.12926]

274 **Roman M**, Monaghan A, Serraino GF, Miller D, Pathak S, Lai F, Zaccardi F, Ghanchi A, Khunti K, Davies MJ, Murphy GJ. Meta-analysis of the influence of lifestyle changes for preoperative weight loss on surgical outcomes. *Br J Surg* 2019; **106**: 181-189 [PMID: 30328098 DOI: 10.1002/bjs.11001]

275 **Adrianzén Vargas M**, Cassinello Fernández N, Ortega Serrano J. Preoperative weight loss in patients with indication of bariatric surgery: which is the best method? *Nutr Hosp* 2011; **26**: 1227-1230 [PMID: 22411364 DOI: 10.1590/S0212-16112011000600005]

276 **Lee Y**, Dang JT, Switzer N, Malhan R, Birch DW, Karmali S. Bridging interventions before bariatric surgery in patients with BMI ≥ 50 kg/m2: a systematic review and meta-analysis. *Surg Endosc* 2019; **33**: 3578-3588 [PMID: 31399947 DOI: 10.1007/s00464-019-07027-y]

277 **Romeijn MM**, Kolen AM, Holthuijsen DDB, Janssen L, Schep G, Leclercq WKG, van Dielen FMH. Effectiveness of a Low-Calorie Diet for Liver Volume Reduction Prior to Bariatric Surgery: a Systematic Review. *Obes Surg* 2021; **31**: 350-356 [PMID: 33140292 DOI: 10.1007/s11695-020-05070-6]

278 **Holderbaum M**, Casagrande DS, Sussenbach S, Buss C. Effects of very low calorie diets on liver size and weight loss in the preoperative period of bariatric surgery: a systematic review. *Surg Obes Relat Dis* 2018; **14**: 237-244 [PMID: 29239795 DOI: 10.1016/j.soard.2017.09.531]

279 **Naseer F**, Shabbir A, Livingstone B, Price R, Syn NL, Flannery O. The Efficacy of Energy-Restricted Diets in Achieving Preoperative Weight Loss for Bariatric Patients: a Systematic Review. *Obes Surg* 2018; **28**: 3678-3690 [PMID: 30121854 DOI: 10.1007/s11695-018-3451-1]

**Footnotes**

**Conflict-of-interest statement:** None of the authors has any conflict of interest.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** June 23, 2021

**First decision:** July 15, 2021

**Article in press:** August 25, 2021

**Specialty type:** Endocrinology and metabolism

**Country/Territory of origin:** India

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): 0

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Mrozikiewicz-Rakowska B **S-Editor:** Yan JP **L-Editor:** Filipodia **P-Editor:** Wang LYT

**Table 1 Evidence grading system for recommendations**

|  |  |
| --- | --- |
| **Level of evidence** | **Description** |
| A | Clear evidence from well-conducted, generalizable randomized controlled trials that are adequately powered, including: Evidence from a well-conducted multicenter trial; Evidence from a meta-analysis that incorporated quality ratings in the analysis. Compelling nonexperimental evidence, *i.e.* "all or none" rule developed by the Centre for Evidence-Based Medicine at the University of Oxford. Supportive evidence from well-conducted randomized controlled trials that are adequately powered, including: Evidence from a well-conducted trial at one or more institutions; Evidence from a meta-analysis that incorporated quality ratings in the analysis |
| B | Supportive evidence from well-conducted cohort studies: Evidence from a well-conducted prospective cohort study or registry; Evidence from a well-conducted meta-analysis of cohort studies. Supportive evidence from a well-conducted case-control study |
| C | Supportive evidence from poorly controlled or uncontrolled studies: Evidence from randomized clinical trials with one or more major or three or more minor methodological flaws that could invalidate the results. Evidence from observational studies with high potential for bias (such as case series with comparison with historical controls); Evidence from case series or case reports. Conflicting evidence with the weight of evidence supporting the recommendation |
| E | Expert consensus or clinical experience |

**Table 2 Obesity classification system for adults: International and Asian**

|  |  |  |
| --- | --- | --- |
| **Category** | **WHO International classification BMI (kg/m2)** | **Asian classification BMI (kg/m2)** |
| Underweight  | < 18.5 | < 18.5 |
| Normal weight | 18.5-24.9 | 18.5-22.9 |
| Overweight | 25.0-29.9 | 23-24.9 |
| Obesity class I | 30.0-34.9 | 25-29.9  |
| Obesity class II | 35.0-39.9 | 30-34.9  |
| Obesity class III | ≥ 40 | ≥ 35 |

BMI: Body mass index.

**Table 3 Indications for metabolic surgery in obesity along with presence of diabetes**

|  |  |  |  |
| --- | --- | --- | --- |
| **Condition** | **Glycemic status** | **Recommendation for metabolic surgery** | **Evidence category** |
| Diabetes and BMI ≥ 40 kg/m2 (≥ 37.5 kg/m2 for Asians) | Any | Strong recommendation  | A |
| Diabetes and BMI 35-39.9 kg/m2 (32.5-37.4 kg/m2 for Asians) | Uncontrolled despite optimal treatment | Moderate recommendation | B |
| Diabetes and BMI 30-34.9 kg/m2 (27.5-32.4 kg/m2 for Asians) | Uncontrolled despite optimal treatment | Weak recommendation | C, E |
| Diabetes and obesity (BMI – not defined) with comorbidities: Poorly controlled hypertension; Non-alcoholic fatty liver disease; Obstructive sleep apnea; Obesity hypoventilation syndrome; Osteoarthritis of the knee or hip; Urinary stress incontinence; Polycystic ovary syndrome; Gastro-esophageal reflux disease; Idiopathic intracranial hypertension; Severe venous stasis disease; Obesity-related limited mobility; Obesity-related poor quality of life | Any | Weak recommendation | E |

BMI: Body mass index.

**Table 4 Comparison between laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy, the two most commonly performed bariatric procedures, in patients with diabetes and obesity**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **RYGB** | **LSG** | **Comments** |
| **Type of procedure** | Combined malabsorptive and restrictive | Restrictive |  |
| **Effect on weight loss** | +++ | +++ | Most studies demonstrate comparable weight loss, with slight superiority of RYGB shown in some reports |
| **Remission of diabetes** | +++ | ++ | RYGB superior to LSG  |
| **Short term glycemic improvement** | +++ | ++ | RYGB superior to LSG |
| **Long term glycemic improvement** | +++ | ++ | RYGB superior to LSG |
| **Improvement in hypertension** | ++ | + | RYGB superior to LSG |
| **Improvement in dyslipidemia** | ++ | + | RYGB superior to LSG |
| **Improvement in gastroesophageal reflux disease** | ++ | + | RYGB superior to LSG |
| **Postoperative complications** | + | +/- | Postoperative complication and reoperation rates less with LSG than RYGB |
| **Long-term nutritional deficiencies** | ++ | + | LSG safer that RYGB |

LSG: Laparoscopic sleeve gastrectomy; RYGB: Laparoscopic Roux-en-Y gastric bypass.

**Table 5 Preoperative evaluation before metabolic surgery in individuals with diabetes and obesity**

|  |  |  |  |
| --- | --- | --- | --- |
| **System** | **Essential evaluation** | **Conditional evaluation** | **Comments** |
| **History and physical examination** | Detailed evaluation along with drug history  | - | - |
| **Glycemic**  | FPG, PPG, HbA1c, Fasting serum C-peptide | SMBG; CGMS | HbA1c < 7% is a reasonable target, higher targets may be acceptable in long-standing diabetes; SMBG and/or CGMS in patients on insulin |
| **Cardiovascular**  | BP: Fasting lipid Profile; ECG: Cardiovascular risk assessment with a validated risk prediction model1 | Transthoracic echocardiography (in cases with unexplained dyspnea and known cases of heart failure, especially with recent changes in clinical status); If risk ≥ 1%,2 functional status assessment. Poor (< 4 METs) or unknown functional capacity - exercise or pharmacological stress echocardiography or radionuclide MPI | Target BP < 140/90; Abnormal results in a stress test should be managed according to current clinical practice guidelines. Patients with underlying cardiac abnormalities should undergo a formal cardiology consultation before surgery |
| **Pulmonary** | Smoking history. Screening for OSA by a clinical scoring tool3. .Risk assessment for VTE during perioperative period by a validated method4 | Pulmonary function testin presence of intrinsic pulmonary disease; Overnight polysomnographyif indicated from results of scoring tool. ABG for PaCO2estimation and venous bicarbonate in cases of OSA to rule out OHS | Structured tobacco cessation program if applicable |
| **Gastrointestinal** | - | UGIE to be considered routinely before LSG. Conditional for other procedures; H pylori detection and eradication |  |
| **Hepatic** | LFT | Abdominal USG if LFT deranged or symptomatic biliary disorder. Use of Noninvasive scoring systems5 can be considered. Liver elastography; Three-dimensional magnetic resonance elastography; Intraoperative liver biopsy | The strategy to diagnose NAFLD in bariatric patients is not defined. Variations of liver elastography such as transient elastography, 2-D shear wave elastography, and ARFI can be better modalities in severely obese patients. Intraoperative liver biopsy is the gold standard, but its specific indications are not clear |
| **Renal, electrolytes, uric acid** | Serum creatinine; eGFR6;Urinary albumin-creatinine ratio | Electrolytes in presence of CKD or drugs known to cause electrolyte imbalance. Uric acidif there is past history of gout | Serum potassium should be measured if on ACE inhibitors, ARBs, or diuretics |
| **Nutritional** | Nutritional assessment by a dietitian. Complete blood count, serum ferritin, serum iron, TIBC, and TS. Serum vitamin B12, folate. Serum calcium, 25(OH)D | Serum C-reactive protein if anemia of chronic inflammation is suspected. Serum methylmalonic acid and homocysteinein cases of low normal vitamin B12 and folate levels with high index of suspicion. Serum copper, zinc, and selenium; fat soluble vitamins such as vitamin A, E and K can be considered before malabsorptive procedures | Serum or urinary N-telopeptide, bone-specific alkaline phosphatase, and bone mineral density can be considered if osteoporosis is suspected especially in postmenopausal women |
| **Endocrine**  | - | Thyroid profile if there is a past history of thyroid dysfunction, goiter or symptoms suggestive of thyroid disorder. ONDST, 24-h urinary free cortisol, or 11-pm salivary cortisol if there is suspicion of endogenous Cushing’s syndrome | Evaluation of syndromic or monogenic obesity on case-by-case basis. |
| **Reproductive** | - | Total and bioavailable testosterone and USG of the pelvis if PCOS is suspected. LH, FSH, and testosterone (total) if hypogonadism is suspected in males | Women should avoid pregnancy if planned for surgery. Pregnancy should be avoided for 12-18 mo after surgery |
| **Psychological** | Behavioral and psychosocial evaluation | **-** | - |

1*e.g.,* Revised Cardiac Risk Index, Obesity surgery mortality risk score, Longitudinal Assessment of Bariatric Surgery consortium risk stratification system, metabolic acuity score, *etc.*

2Estimated perioperative mortality risk or major adverse cardiovascular risk of ≥ 1%.

3STOP-BANG questionnaire or Berlin questionnaire.

4*e.g.,* venous thromboembolism risk assessment tool by Fink *et al*[130].

5Non-alcoholic steatohepatitis clinical scoring system, AST to platelet ratio index, FIB-4 index, non-alcoholic fatty liver disease fibrosis score, BARD score and Forns index.

6By Chronic Kidney Disease Epidemiology Collaboration formula.

25(OH)D: 25-hydroxyvitamin D; ABG: Arterial blood gas; ACE: Angiotensin converting enzyme; ARB: Angiotensin II receptor blocker; ARFI: Acoustic radiation force impulse shear wave imaging; CGMS: Continuous glucose monitoring system; eGFR: Estimated glomerular filtration rate; FPG: Fasting plasma glucose; FSH: Follicle-stimulating hormone; *H. pylori*: *Helicobacter pylori*; HbA1c: Glycated hemoglobin; LFT: Liver function test; LH: Luteinizing hormone; MET: Metabolic equivalent; MPI: Myocardial perfusion imaging; ONDST: Overnight dexamethasone suppression test; OSA: Obstructive sleep apnea; PCOS: Polycystic ovary syndrome; PPG: Post-prandial glucose; SMBG: Self-monitoring of blood glucose; TIBC: Total iron-binding capacity; TS: Transferrin saturation; UGIE: Upper gastrointestinal endoscopy; USG: Ultrasonography; VTE: Venous thromboembolism.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2021 Baishideng Publishing Group Inc. All rights reserved.**